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ABSTRACT 
Single photon emission computed tomography (SPECT) with a superior contrast 
resolution has been shown to be more sensitive and specific with a lower non-
diagnostic rate than planar imaging in many nuclear medicine studies but it is still not 
being routinely implemented in V/Q studies at many centres including Tygerberg 
Hospital. There are many studies on V/Q SPECT using Technegas as a ventilation 
agent but very limited studies available on 81m Kr gas. 
Aim: To clinically compare conventional planar and SPECT V/Q imaging using 81mKr 
gas in the diagnosis of pulmonary embolism, with CTPA as the gold standard. 
 
Patients and Methods: All patients referred with clinical suspicion of pulmonary 
embolism were assessed. The inclusion criteria were normal chest radiograph, 
normal renal function and no contrast allergy. Exclusion criteria were age below 18 
years old, pregnancy, abnormal chest radiograph, abnormal serum creatinine/urea 
levels and unstable patients. A Well’s score was assigned to each enrolled patient. 
Perfusion scintigraphy was performed after intravenous injection 125 MBq of 99mTc 
MAA. Ventilation scintigraphy was performed with 81mKr gas. On a dual head 
camera, SPECT was done before planar acquisition, while perfusion was done 
before ventilation imaging in the same position. Planar V/Q images consisted of 6 
standard views. All V/Q SPECT images were reconstructed using ordered-subset 
expectation-maximization (OSEM) algorithm and a post-reconstruction 3D 
Butterworth filters were applied. V/Q Planar and V/Q SPECT images were later 
evaluated and reviewed separately and reported based on recent EANM guidelines 
blinded to the CTPA results. 
All patients underwent multi-slice CTPA examinations on a 40-detector row scanner. 
The images were later assessed and reported blinded to the V/Q results. 
Statistical analysis was done using the Fisher exact test for comparison of 
categorical variables and the one-way ANOVA for continuous variables (p<0.05 was 
significant). 
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Results: A total of 104 consecutive patients were referred with clinical suspicion of 
pulmonary embolism. Seventy-nine patients were excluded from this study mostly 
due to abnormal serum creatinine/urea levels. Only 25 patients were included in this 
study, with a mean age of 48 ± 19 years, and 64% being females. When compared 
to CTPA as gold standard, the prevalence of PE was 16% [5% – 37% at 95% CI], 
sensitivity 75% [21% – 99% at 95% CI], specificity 90% [68% – 98% at 95% CI], 
positive predictive value 60% [17% – 93% at 95% CI], negative predictive value 95% 
[73% – 100% at 95% CI] and diagnostic accuracy 88% [69% – 97%at 95% CI] for 
both V/Q Planar and SPECT. V/Q Planar showed a lower reader confidence i.e. 
could only clearly resolve 72% of cases compared to V/Q SPECT, which could 
precisely interpret all cases, showed more and better delineated mismatch vs match 
and segmental vs non-segmental defects. All patients who were scored as PE 
unlikely on Wells’ score (4) had PE ruled out on CTPA (p=0.04581) as well as 89% 
of patients on V/Q SPECT and V/Q Planar. 
 
Conclusion: Based on this study, V/Q Planar and V/Q SPECT have a similar 
diagnostic performance in patients with a normal or near normal chest X-rays. 
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OPSOMMING 
Enkelfoton emissie rekenaartomografie (EFERT) met beter kontrasresolusie is 
bewys om meer sensitief en spesifiek met ‘n laer nie-diagnostiese opbrengs as 
planare beelding in verskeie kerngeneeskunde ondersoeke te wees. In Tygerberg 
Hospitaal, soos in verskeie ander sentra, word dit egter steeds nie roetineweg vir 
ventilasie-perfusiestudies (V/Q) geïmplementeer nie. Daar is verskeie EFERT V/Q 
studies met Technegas as ventilasie agens, maar beperkte studies met 81m Kr gas 
beskikbaar. 
Doel: Om konvensionele planare en EFERT V/Q beelding vir die diagnose van 
pulmonale embolisme met mekaar te vergelyk, met rekenaartomografie pulmonale 
angiografie (RTPA) as goue standaard. 
 
Pasiënte en Metodes: Alle pasiënte wat met ‘n kliniese vermoede van pulmonale 
embolisme verwys is, is geevalueer. Die insluitingskriteria was ’n normale borskas X-
straal, normale nierfunksie en geen kontrasallergie nie. Uitsluitingskriteria was 
pasiënte jonger as 18 jaar, swanger pasiënte, abnormale borskas X-straal, 
abnormale serum kreatinien / ureumvlakke en onstabiele pasiënte. ’n Wells telling is 
vir elke pasiënt wat in die studie ingesluit is, bepaal. 
Perfusiebeelding is uitgevoer na die intraveneuse toediening van 125 MBq 99mTc 
MAA. Ventilasiestudies is gedoen met 81mKr gas. Die V/Q EFERT studies is voor die 
planare beelding met ’n dubbelkop gammakamera uitgevoer. Perfusiebeelding is 
voor die ventilasie in dieselfde posisie verkry. V/Q planare beelding het bestaan uit 6 
standaard beelde. Alle V/Q EFERT is met “ordered-subset expectation-
maximization” (OSEM) algoritmes verwerk, en post-rekonstruksie 3D Butterworth 
filters is toegepas. V/Q planare en V/Q EFERT beelding is later afsonderlik en 
sonder RTPA inligting volgens onlangse EANM riglyne evalueer en gerapporteer. 
‘n Veelsnit RTPA met ‘n 40 snit skandeerder is op alle pasiënte uitgevoer. Die 
beelde is later beoordeel en gerapporteer sonder inagneming van die V/Q 
beeldingsresultate 
Statistiese verwerking is gedoen met die Fisher presisietoets vir vergelyking van 
kategoriese veranderlikes en die eenrigting ANOVA vir kontinue veranderlikes 
(p<0.05 is statisties betekenisvol). 
vi 
 
 
 
Resultate: ‘n Totaal van 104 opeenvolgende pasiënte met ‘n kliniese vermoede van 
pulmonale embolisme is verwys. Nege-en-sewentig pasiënte is uitgesluit, in die 
meeste gevalle as gevolg van abnormale serum kreatinienvlakke. Slegs 25 pasiënte 
is ingesluit, met ’n gemiddelde ouderdom van 48 ± 19 jaar, en 64% vroue. In 
vergelyking met RTPA as goudstandaard, was die prevalensie van PE 16% [5% – 
37% met 95% VI], sensitiwiteit 75% [21% – 99% met 95% VI], spesifisiteit 90% [68% 
– 98% met 95% VI], positiewe voorspellingswaarde 60% [17% – 93% met 95% VI], 
negatiewe voorspellingswaarde 95% [73% – 100% met 95% VI] en diagnostiese 
akkuraatheid van 88% [69% – 97% met 95% VI] vir beide planare en EFERT V/Q 
beelde. V/Q planare beelde het ‘n laer lesersvertroue getoon, nl. dat slegs 72% van 
gevalle opgelos kon word relatief tot V/Q EFERT beelde, wat in alle gevalle presies 
geïnterpreteer kon word, met meer en beter omskrewe nie-ooreenstemmende 
teenoor ooreenstemmende en segmentele teenoor nie-segmentele defekte. In alle 
pasiënte met ‘n Wells puntetelling van 4 is PE met die RTPA uitgeskakel 
(p=0.04581), terwyl dit in 89% van pasiënte met V/Q EFERT en planare beelde 
uitgeskakel is. 
 
Gevolgtrekking: Gebaseer op hierdie studie het V/Q planare en EFERT beelding ‘n 
ooreenstemmende diagnostiese prestasie in pasiënte met ’n normale of naby 
normale borskas X-straal. 
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DEFINITION OF TERMS 
Pulmonary embolism (PE) = refers only to thrombotic emboli and not non-thrombotic 
emboli (includes fat, air, amniotic fluid). 
 
Mismatch defect = As seen on a V/Q scan, a perfusion defect that ventilates 
normally. Segmental if it is in a whole segment, sub-segmental if less than 50% of a 
segment. 
 
Match defect = As seen on a V/Q scan, a perfusion defect that corresponds to a 
ventilation defect. 
 
Non-segmental defect = As seen on a V/Q scan, it is not pleural based and does not 
conform to known subsegmental or segmental vascular anatomy.  
 
Reverse match defect = As seen on a V/Q scan, a defect that is worse (larger in 
size) on the ventilation image or chest radiograph compared to a corresponding area 
on the perfusion image in keeping with lung parenchymal disease. 
 
PE diagnosis = As seen on a V/Q scan, at least one segmental or two subsegmental 
mismatch perfusion defect(s) that ventilate(s) normally conforming to the pulmonary 
vascular anatomy (according to the recent EANM guidelines). 
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LIST OF ABBREVATIONS 
(In alphabetical order) 
0C = degrees Centigrade 
81Rb = Rubidium 81 
81mKr = metastable Krypton 81 
133Xe = Xenon 133 
99mTc = metastable Technetium 99 
2D = 2 dimensional 
3D = 3 dimensional 
µm = micrometres 
ANT = anterior 
BMI =Body mass index 
bpm = beats per minute 
COPD = Chronic obstructive pulmonary disease 
CT = Computed Tomography 
CTPA = Computed Tomographic Pulmonary Angiography 
CTV = Computed Tomographic Venography 
DSPA =Digital subtraction pulmonary angiography 
DTPA = diethylenetriaminepentaacetic acid  
DVT = Deep venous thrombosis 
EANM = European Association of Nuclear Medicine 
ECG = Electrocardiography 
ECHO = Echocardiography 
Gd- MRA = gadolinium-enhanced Magnetic Resonance Angiography 
HU = Hounsfield unit 
IAEA = International Atomic Energy Agency  
kcps = kilocounts per second 
kcts = kilocounts 
keV = kiloelectronVolts 
kV = kiloVolts 
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LAO= Left Anterior Oblique 
LEHR = Low Energy High Resolution 
LLAT = Left Lateral 
LPO = Left Posterior Oblique 
mA = milliAmperes 
MAA = macroaggregates of albumin 
MBq = MegaBequerels 
mCi = milliCurie 
mGy = milliGrays 
MIP = maximum intensity projection 
mg = milligram 
ml = millilitres 
mm = millimetres 
mmHg = millimetres of Mercury 
MR = Magnetic Resonance 
MRA= Magnetic Resonance Angiography 
MRV = Magnetic Resonance Venography 
mSv = milliSiverts 
ng = nanogram 
nm = nanometre 
NPV = Negative predictive value 
P = Perfusion 
PE = Pulmonary embolism 
PERF = Perfusion 
PTE = pulmonary thromboembolism 
PIOPED = Prospective investigation of pulmonary embolism diagnosis 
PISA-PED = Prospective Investigative Study of Acute Pulmonary Embolism 
Diagnosis  
POST = Posterior 
PPV = Positive predictive value 
Q = Perfusion 
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rad = Unit for radiation absorbed dose 
RAO = Right Anterior Oblique 
RLAT = Right Lateral 
RPO = Right Posterior Oblique 
s = seconds 
SLE = Systemic Lupus Erythematosus 
SNM = Society of Nuclear Medicine 
SPECT = Single Photon Emission Computed Tomography 
SPECT/CT = Single Photon Emission Computed Tomography with (low dose) X-ray 
Computed Tomography 
TM = Trademark 
USS = Ultrasonography 
V = Ventilation 
Vent = Ventilation 
VTE = Venous thromboembolism 
V/Q = Ventilation/ Perfusion 
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INTRODUCTION 
Pulmonary embolism is an important cause of morbidity and mortality. The diagnosis 
of pulmonary embolism remains problematic because clinical symptoms and signs 
are mimicked by other disorders. Pulmonary imaging procedures lack certainty, and 
patient co-morbidities may limit the utility of certain tests. The availability of a simple, 
accurate, non-invasive diagnostic test would be very beneficial to assist with the 
diagnosis of pulmonary embolism.1,2 
 
Ventilation/Perfusion (V/Q) scintigraphy is able to visualize pulmonary emboli 
indirectly. Multi-detector Computed Tomography Pulmonary Angiography (CTPA) 
visualizes pulmonary emboli directly but no reliably safe gold standard is available. 
Difficulties arise in expressing the results of both V/Q scintigraphy and CT in terms of 
sensitivity, specificity and accuracy.3 
 
Since time immemorial, the management of patients with non-diagnostic V/Q scans 
has been problematic. The incidence of pulmonary embolism was too low to 
recommend the empiric treatment of all patients. However, not treating any patient 
having a non-diagnostic lung scan with anticoagulants would be fraught with risk. 
Although high probability and normal V/Q scan reports are very useful findings to 
rule in or out pulmonary embolism respectively, most patients (44% in the PIOPED 
study) undergoing V/Q scanning had non-diagnostic results (intermediate or 
indeterminate probability) in whom the incidence of pulmonary embolism may vary 
from 10% to 30%.4,5 
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Over the years, mortality from acute PE has declined as increasingly safe methods 
of investigation have become more widely available.6 The question is whether 
clinicians really know how to investigate patients with pulmonary embolism? 
Clinicians in the UK were assessed using a clinical questionnaire based on British 
Thoracic Society (BTS) guidelines by McQueen et al.7 It came to light that, the 
majority of the doctors did not agree that a negative CTPA or lung scintigraphy 
excluded PE and thus a need to identify methods to improve this situation.7 
 
Computed tomography (CT) scans account for the largest population radiation dose 
in medical diagnostic studies. High and accumulative radiation doses may initiate or 
promote carcinogenesis. There is a need for radiation dose reduction by seeking 
alternative and accurate imaging strategies.8 
 
Single photon emission computed tomography (SPECT) has replaced planar 
imaging in many areas of nuclear medicine. Given its superior contrast resolution 
and improved anatomical detail, SPECT (and more recently SPECT/CT) is used in 
lieu of planar imaging for cardiac and brain scanning and as an adjunct to planar 
scintigraphy in many other areas, such as bone, infection and tumor imaging. Given 
the improvements in sensitivity and diagnostic accuracy that have generally 
accompanied the transition from two-dimensional planar to three-dimensional (3D) 
imaging, it is surprising that only a limited number of centers routinely utilize the 
SPECT technique with V/Q scintigraphy, one of the most commonly performed 
diagnostic studies in nuclear medicine.9 
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LITERATURE REVIEW 
The Lungs – Anatomy and Physiology 
The airway of the respiratory tract starts at the nostrils and passes the pharynx and 
then through the trachea. The trachea divides into right and left main stem bronchi to 
enter each lung; these in turn divide to form lobar bronchi which further divide into 
bronchioles and then finally alveoli. In the lungs, there are three lobar divisions on 
the right i.e. upper-, middle- and lower- lobes and two lobar divisions on the left i.e. 
upper- and lower- lobes. The lobes are further divided into broncho-pulmonary 
segments. The knowledge of such broncho-pulmonary segments (Figure 1 and 
Figure 2) is vital for interpretation of radionuclide images. Each broncho-pulmonary 
segment is made up of alveoli as the terminal respiratory units. An alveolus has an 
average diameter of 150µm and an adult human has about 700 million alveoli with a 
surface area of 80m2. Apart from the direct pathway, air can get to the alveoli 
through indirect pathways such as the pores of Kohn and canals of Lambert. These 
indirect pathways allow collateral ventilation and prevent collapse of an obstructed 
broncho-pulmonary segment or segments. The lungs are lined on the outside by a 
visceral membrane while the thoracic cavity is lined on the inside by a parietal 
membrane forming the pleural cavity in between, containing serous fluid – a lubricant 
during breathing.10,11 
 
 - 4 - 
 
 
The main pulmonary arteries carry de-oxygenated blood from the right ventricle of 
the heart and divide in each lung to follow the broncho-pulmonary segmental airway 
pattern while the pulmonary vein carries oxygenated blood to the left atrium, which is 
then pumped to the systemic circulation via the left ventricle and the aorta.11 
 
The pulmonary artery branches into distribution arteries of diameter ranging from 60 
to 100m. These arteries branch into precapillary arterioles with diameters of 25 to 
35m which terminate in alveoli capillary units of average diameter 8m – large 
enough to allow passage of red blood cells (7m) without deforming them. There are 
about 280 billion arterial capillaries and approximately 500 to 1000 capillaries 
surrounding each alveolus. Deoxygenated blood carried by arterial capillaries rapidly 
exchanges its carbon dioxide for inhaled oxygen at the alveoli membranes; carbon 
dioxide released is exhaled.11  
 
Lungs also receive blood from the aorta via the bronchial arteries which follow the 
bronchial tree to finally anastomose at the capillary level with the pulmonary 
circulation. The bronchial circulation supplies about 5 to 6% of the lung blood 
supply.10,11 
 
Ventilation and perfusion vary with gravity and position. In the upright position, both 
ventilation and perfusion increase progressively from apices to bases due to a 
progressive increase in intra-pleural pressure and gravitational blood supply  
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respectively – such a gradient is more prominent for perfusion than ventilation. In the 
supine position, both ventilation and perfusion have a relatively uniform distribution 
throughout the lungs.10 
 
Acute changes in perfusion such as local ischaemia and hypoxia, affect ventilation 
by causing a reflex bronchoconstriction which leads to a shift in ventilation from 
hypoperfused areas – this phenomenon rarely occurs in humans. Commonly, lung 
parenchyma remains viable in PE despite loss of pulmonary artery blood supply due 
to the alternative bronchial arterial system. Therefore, normal alveolar spaces will 
remain aerated without infarcting. This is the basis of the V/Q mismatch in PE. 
However, abnormalities in ventilation commonly cause redistribution of perfusion 
away from hypoventilated regions.10 
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Figure 1 Broncho-pulmonary segments of the lungs (from www.nucmedinfo.com) 
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Figure 2 Broncho-pulmonary segmental map of the lungs on SPECT as frontal or coronal slices from anterior to posterior (above) 
and sagittal slices from right to left periphery (below). Key to segments: an=anterior; ap=apical; p=posterior; l=lateral; m=medial; 
s=superior (and superior lingula on the left lung); i=inferior lingula; ab=anterior basal; mb=medial basal; lb=lateral basal; 
pb=posterior basal. (from EANM guidelines for ventilation/perfusion scintigraphy part 1 Eur J Nucl Med Mol Imaging 2009; 36:1359)  
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PULMONARY EMBOLISM 
Acute pulmonary embolism (PE) is characterised by partial or complete obstruction 
of central or peripheral arteries of the lungs by emboli. Not only the disease itself but 
also the anticoagulant treatment of PE may entail substantial morbidity.12 There is a 
need for prompt and accurate diagnosis. However, the clinical diagnosis of PE has 
proven to be difficult, since clinical signs and symptoms are often non-specific.13 In 
fact, in only up to one-third of patients clinically suspected of having PE is the 
diagnosis subsequently established.14 
 
Epidemiology of PE 
Acute PE is the third most common cause of death after cardiovascular diseases 
and malignancies and also the third most-common cause of cardiovascular death 
after myocardial ischemia and stroke.15 PE is the leading cause of maternal death in 
pregnancy.16,17 
 
PE is a common disorder, with an estimated annual incidence of 23 to 69 per 
100,000 in a community.18,19 The incidence of PE rises with age, approaching 
approximately 1 in 100 in the very old. In the absence of risk factors, PE is rare in 
children under 15 years of age (<5 per 100,000).20 
 
The fatality from PE can be as high as 10% within the first hour.21 Untreated PE is 
associated with a mortality rate of 15 to 30% across all age groups22 rising to 58% in 
haemodynamically unstable patients.1 
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Conversely, the fatality during anticoagulation therapy has been reduced to 0.4% in 
patients presenting with deep venous thrombosis (DVT) and 1.5% in those 
presenting with PE of thrombotic origin.23 
 
Natural History of PE 
Pulmonary embolism usually arises from deep vein thrombosis of the lower 
extremities.24 Further evidence that DVT and PE are distinct manifestations of the 
same disease process referred to as venous thromboembolism (VTE), comes from 
the observation that in the majority of patients with PE, DVT can be diagnosed using 
sensitive methods. In patients with proven leg vein DVT, 40% have asymptomatic 
PE.25 Mortality is higher for PE than for DVT.20 
 
Usually, deep vein thrombosis originates in leg veins of the calf and propagates to 
the proximal leg veins.24 Patients with deep vein thrombosis involving the proximal 
leg veins are considered at greatest risk for developing pulmonary embolism (as 
opposed to those with isolated calf vein thrombosis). It is hypothesized that isolated 
calf vein thrombosis may be a clinically self-limiting condition and patients become at 
risk for pulmonary embolism if the thrombus propagates to the proximal venous 
system.24,26 
 
With time, the thrombosis will extend in a contiguous fashion to involve the more 
proximal venous system of the legs; the popliteal, superficial femoral, and common 
femoral veins. Less commonly, deep vein thrombosis originates in the iliac veins  
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and, with time, will spread distally. Iliofemoral or pelvic deep vein thrombosis tends to 
occur in certain settings such as pregnancy or in the presence of pelvic masses and 
post surgery in gynaecological, urological or abdominal procedures. The thrombus 
dislodges from the deep veins, travelling through the inferior vena cava and the right 
heart to finally lodge in the pulmonary arterial system or paradoxically to the 
systemic arterial circulation via a patent foramen ovale or atrial septal defect.24,27-2927, 28, 29 
 
PE may less commonly originate from other venous sources. Particularly, with the 
chronic use of upper extremity indwelling catheters, pulmonary embolism may arise 
from the veins in the upper extremities. The de novo development of pulmonary 
embolism is thought to be uncommon.24,30,31 
 
In the International Cooperative Pulmonary Embolism Registry (ICOPER) set up to 
determine baseline mortality rates and mechanisms of death in pulmonary embolism, 
the 3-month overall mortality rate was 15% and the factors that were significantly 
associated with increased mortality were systolic arterial hypotension, congestive 
heart failure, cancer, tachypnoea, right ventricular hypokinesia, chronic obstructive 
pulmonary disease (COPD), and age >70 years.1 
 
The most feared long-term consequence of untreated or poorly treated acute PE is 
chronic thrombo-embolic pulmonary hypertension, a severely debilitating and 
potentially fatal condition.32-34 32,33,34 
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Pathophysiology of PE 
Three factors known as the Virchow’s triad (Figure 3) contribute to the development 
of venous thrombosis: hypercoagulability, stasis and endothelial injury. A German 
physician Rudolf Virchow (1821-1902) coined the two terms, venous thrombosis and 
pulmonary embolism. Interestingly, Virchow only began to be routinely credited with 
this triad one hundred years after publication of his work on venous thrombosis. This 
acknowledgement coincided with the accumulation of experimental evidence for the 
role these factors play in thrombogenesis.35 
 
Figure 3 Virchow’s triad (from www.thrombosisadviser.com) 
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Acquired and genetic factors can predispose to venous thromboembolism. Among 
the acquired factors include long distance flights, obesity, smoking, oral 
contraceptives, postmenopausal hormone replacement, pregnancy, surgery, trauma 
and medical conditions such as antiphospholipid antibody syndrome, malignancy, 
systemic arterial hypertension and chronic obstructive pulmonary disease. Genetic 
predisposing factors are present in only a minority of patients such as thrombophilia, 
as well as factor V Leiden and the prothrombin gene mutation (the two most 
common autosomal dominant genetic mutations).29,36 
 
The haemodynamic effects of major PE on the circulation and may include37; 
 Ventilation of unperfused regions will cause increased dead space38 – this is 
one reason for dyspnoea. Other reasons for dyspnoea are impaired gaseous 
exchange, alveolar hyperventilation, increased airway resistance and 
decreased pulmonary compliance.37 
 Emboli occluding pulmonary end arteries may lead to haemorrhage, pleuritic 
pain, pleural effusion and atelectasis. The lung has no pain fibres. Pain with 
PE indicates involvement of parietal pleura.37 
 Increased pulmonary vascular resistance and pulmonary hypertension due to 
a decrease in the number of normal perfusing lung segments, leads to right 
ventricle strain, right ventricular dysfunction (electromechanical dissociation), 
hypotension, syncope and sudden death may follow.37 
 An increase in right atrial pressure can lead to a right to left shunt through a 
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patent foramen ovale contributing to hypoxaemia. The shunt can also lead  
to paradoxical emboli, implying that thrombus of venous origin causes 
infarctions in the aortic distribution, commonly the brain.39 
 
Clinical Presentation of PE 
The clinical spectrum ranges from asymptomatic to sudden death. The majority of 
patients with PE present with recognized patterns of symptoms and signs that may 
include unexplained breathlessness, chest pain (central or pleuritic), cough, 
haemoptysis, syncope, palpitations, tachypnoea, tachycardia (heart rate >100 beats 
per minute), cyanosis, fever, hypotension (systolic blood pressure <100 mmHg), right 
heart failure, pulmonary hypertension and leg swelling.40 
 
Clinical syndromes29 of PE include; 
 Massive PE – if hemodynamically unstable manifested by systemic 
hypotension or shock (systolic BP  90mmHg and/or the use of vasopressor 
therapy). Traditionally, defined by angiographic obstruction of 50% or 
obstruction of two lobar arteries. 
 Moderate to large PE – have right ventricular hypokinesis on 
Echocardiography but are normotensive. 
 Small to moderate PE – have normal cardiac function as well as being 
normotensive. 
 Pulmonary infarction – not uncommon in PE (complete or incomplete infarct 
has been observed in 70% of patients with PE at post-mortem)41 and is very  
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painful if in proximity to pleural nerves but may be present in any of the above 
syndromes. 
 Non-thrombotic PE – may be due to air, fat, amniotic fluid, sepsis, tumor and 
substance abuse (hair, cotton or talc powder). 
 
Differential diagnoses of pulmonary embolism include acute coronary syndrome, 
congestive cardiac failure, pericarditis, pneumonia, chronic obstructive airway 
disease (COPD), pleurisy, primary pulmonary hypertension, costochondritis (Tietze’s 
syndrome), and anxiety disorders.29 
 
According to the PIOPED II study, signs and symptoms are similar in both the young 
and the elderly except that dyspnoea or tachypnoea is less frequent in the elderly, 
who have no history of cardiopulmonary disease. Typical symptoms and signs may 
even be absent in patients with severe PE. The haemoptysis/pleuritic pain 
syndrome, uncomplicated dyspnoea syndrome or circulatory collapse syndrome 
typical of PE are more common in proximal artery PE (94% of patients) than 
segmental artery PE (72% of patients).40 
 
While certain symptoms and signs are more commonly observed in PE than in other 
conditions, it is not possible to confirm a diagnosis of PE on clinical features alone. 
The diagnosis of PE must be confirmed or refuted on the basis of a conclusive 
imaging test.42,43 
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Diagnosis of Pulmonary Embolism  
Prompt and accurate diagnosis of pulmonary embolism has been shown to greatly 
influence patient outcome. More than 30% of untreated patients with PE will die, 
compared with less than 10% of treated patients.15,44 Accordingly, it is important to 
quickly and accurately diagnosis PE. When evaluating a patient with suspected PE, 
it is important to remember that PE is only one part of venous thrombo-embolic 
disease. The other part is the venous thrombus that commonly forms in a lower 
extremity vein, and subsequently migrates into the pulmonary arterial circulation. 
 
Many tests and algorithms have been suggested for the evaluation of patients with 
suspected VTE, from the history and physical examination to blood analysis, 
electrocardiogram, echocardiography, chest radiography, ventilation/perfusion 
scintigraphy, catheter pulmonary angiography, CT and MR pulmonary angiography, 
lower-extremity vein sonography, CT venography and MR venography. 
 
The main challenge in the diagnostic work-up of patients with clinically suspected PE 
is to accurately and rapidly distinguish the 25% of patients (the approximate 
proportion of patients who test positive for PE in most population groups) who have 
the disease and require anticoagulant therapy from the 75% who do not have PE.45 
 
Over the years, mortality from acute PE has declined as increasingly safe methods 
of investigation have become more widely available.7 
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NON-IMAGING 
Clinical Probability Testing for PE 
Clinical acumen is the mainstay for raising the suspicion of acute PE in the 
early approach to patients, especially if presenting with atypical and/or 
equivocal symptoms. On the other hand, wise judgement should guide the 
sequential choice of diagnostic tests required to confirm or exclude the actual 
occurrence of PE, and should also guide interpretation of the results obtained 
(mostly consisting of the application of imaging modalities). These 
considerations emphasize the need for a multidisciplinary approach to the 
diagnosis of PE. Therefore, the desire for round-the-clock availability of a 
team of specialists, each possessing specific competence in the different 
medical fields involved with PE.45 
 
The PIOPED II investigators recommended stratification of all patients 
suspected of having PE according to an objective clinical probability 
assessment. PIOPED II, which primarily studied the accuracy of CTPA, 
showed a poor positive predictive value (PPV) of only 58% when the CTPA 
results and pretest probability was discordant.40 A conclusion of PIOPED II 
was that when results of imaging are discordant with pretest probability, 
further investigation is needed.40 Interestingly, a similar poor performance 
(PPV of 56%) was noted when V/Q scintigraphy results were discordant with 
pretest probability in PIOPED.4 
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Many patients presenting with leg pain or swelling, chest pain or dyspnoea, 
when investigated, end up being DVT or PE negative and, conversely, many 
are not investigated when VTE should have been suspected in the first 
place.46 Furthermore, many clinical practitioners fail to realize the limitations of 
imaging tests. It has been suggested that physicians should always take a 
careful history and physical examination and, in many cases, perform an 
electrocardiogram and chest x-ray before using these clinical probability 
tools.47 
 
Evidence suggests a strategy that uses clinical probability and the D-dimer 
test will be most the cost-effective.48 However, comparative analyses of CTPA 
and V/Q scanning are lacking. Wells et al47 performed a comparative analysis 
of a randomized study where it was deducted that although CTPA is more 
effective at preventing overall mortality, the CTPA strategy has an incremental 
cost of more than $27,000 per life year saved compared with V/Q scanning. 
 
An ideal scoring system aimed at assessing the pretest probability of any 
disease requiring prompt therapeutic intervention (such as acute PE), should 
be designed so as to keep to a minimum the proportion of patients classified 
as “intermediate probability”.45 
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The Wells and coworkers model49 has been used in at least 12 studies, and 
more than 10,000 patients have been evaluated, including 5 studies with a 
total of more than 5800 patients in which the authors used the dichotomous 
scoring system of PE unlikely (score 4) or PE likely (score >4) (Table 1). 
Simply posting the model in the clinic area has proven useful in one centre.47 
 
The Wells model seems better suited to rule out rather than to rule in the 
diagnosis of PE, and its performance is likely to be better in clinical settings 
where the prevalence of the disease is expected to be low.47 
 
Table 1 The Wells and coworkers model47 
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Recently, a more precise prediction model (the simplified Pisa model) 50 was 
introduced which depends on 16 variables including older age, risk factors, 
pre-existing cardiopulmonary diseases, relevant clinical symptoms and signs, 
and the interpretation of the electrocardiogram (Table 2). In contrast to other 
prediction rules, the model includes variables that are negatively associated 
with PE. This gives the model greater flexibility, which may explain why it 
performs equally well in detecting and excluding PE. Instead of using a point-
scale score proportional to the regression coefficients, typical of other 
approaches such as the Wells score as described above, the Geneva score51 
and the Hamilton score52, the probability of PE is estimated directly from the 
algebraic sum of the regression coefficients. This allows prediction of the 
clinical probability as a continuous function and it estimates likelihood ratios 
for PE precisely.53 
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Table 2 Clinical prediction model for PE (simplified Pisa model) 
 
(from http://www.ifc.cnr.it/pisamodel). 
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Blood Analysis 
i.  Plasma D-dimer levels 
D-dimer is a specific breakdown product of cross-linked fibrin in blood clots. 
D-dimer is thus elevated in the setting of deep venous thrombosis and 
pulmonary embolism.5,49 
 
The plasma D-dimer enzyme-linked immunosorbent assay (ELISA) has 
become recognized as a sensitive screening test for excluding acute 
pulmonary thromboembolism. Quantitative assay of D-dimer, based on a 
rapid ELISA method, has a high sensitivity (about 95%) for venous 
thromboembolism. Other numerous qualitative and quantitative D-dimer 
assays have been introduced. One quantitative assay, the immuno-
turbidimetric assay, has been shown to be equivalent to the ELISA.54 
 
A negative D-dimer result is potentially useful in excluding acute pulmonary 
thromboembolism, with reported negative predictive values of 91–100%.5,55-57 55,56,57 
D-dimer measurement by the Elisa test is very promising since it can exclude 
nearly 30% of patients with suspected PE without any further investigation on 
the basis of a D-dimer level less than 500 ng/ml.58 Venous thromboembolism 
event rates were less than 0.5%.in follow-up data on patients in whom PE 
was ruled out on the basis of clinical probability (low probability or PE unlikely) 
and negative D-dimer testing.59,60 
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On the contrary, a positive D-dimer result is of limited value in hospitalized or 
critically ill patients, the elderly, pregnancy, infection and inflammation, 
trauma, neoplasia, and post-operative states, since all are independently 
associated with elevated D-dimer levels; hence, it cannot be used to triage 
such patients.5,55-57 
 
If patients have a high pretest probability (PE likely) or a positive D-dimer, 
then imaging, V/Q scan or CTPA is recommended. If the V/Q scan is non-
diagnostic, then lower-extremity venous ultrasound is also recommended. In 
low pretest probability (PE unlikely) patients who have a high-probability V/Q 
scan, it is important to verify the diagnosis with lower-extremity venous 
ultrasound, CTPA or pulmonary angiogram.61 
 
ii.  Brain-type Natriuretic Peptide (BNP) 
The potential role of elevated brain-type natriuretic peptides (BNP) in the 
differentiation of patients suffering from acute pulmonary embolism at risk for 
adverse clinical outcome has not yet been fully established. High BNP or N-
terminal–pro-BNP levels (NT–pro-BNP) distinguish patients with pulmonary 
embolism at higher risk of adverse events and death. Increased BNP 
concentrations alone, however, do not justify more invasive treatment 
regimens. Normal BNP levels might be an indication for outpatient 
treatment.62 
 - 23 - 
 
 
iii.  Arterial Blood Gases 
Hypoxaemia and respiratory alkalosis are common findings in PE. This was 
confirmed in both the PIOPED and the PISA-PED trials.4,63 However, the 
PISA-PED study found that hypoxaemia and respiratory alkalosis were not 
specific since they were present in 75% of patients who did not have PE.63 
 
Electrocardiography (ECG) 
Classically seen in PE are sinus tachycardia; new-onset atrial fibrillation or 
flutter; an S wave in lead I, a Q wave in lead III; inverted T wave in lead III. 
Often the QRS axis is greater than 90o. More frequent is the T wave inversion 
in leads V1 to V4, right bundle branch block, right axis deviation and, in 
longstanding cases, P-pulmonale reflecting a right ventricular strain.29 
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IMAGING – (no radiation) 
Echocardiography 
Echocardiography is easily transportable, can be performed at the bedside 
which is an added advantage for patients in shock or with severe hypotension 
and can also diagnose emboli in transit in the right atrium or ventricle. Emboli 
in transit are classified as type A or type B thrombi. Type A thrombi are long, 
thin, and extremely mobile, characteristically found in the right atrium and, 
tend to originate in the peripheral deep venous system. These type A thrombi 
are generally found in the high risk group manifesting with severe PE and 
mortality, as such thrombi tend to migrate suddenly to the pulmonary arterial 
system precipitating an acute deterioration. Type B thrombi are usually 
smaller, round or oval-shaped, less mobile and arise in the right ventricle and 
are commonly associated with right ventricle thrombogenetic abnormalities 
(namely, congestive heart failure, pacemaker electrodes, cardiac prostheses). 
Patients with PE arising from type B thrombi have a good prognosis 
independent of the treatment type.64 
 
Normal echocardiograms are seen in 50% of patients with PE.29 
Nevertheless, echocardiography is important in rapidly triaging patients. 
McConnell’s sign demonstrated by right ventricular free wall hypokinesia with 
normal right ventricular apical motion is specific for PE. The presence of right 
ventricular dysfunction determines risk stratification, prognosis and planning 
optimal management.29 
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Echocardiography can also reliably distinguish among other conditions that 
have radically different treatment regimens, including acute myocardial 
infarction, pericardial tamponade and aortic dissection.29 
 
Leg Venous Ultrasonography 
Bilateral compression ultrasonography of the proximal venous system of the 
legs between the popliteal and common femoral veins is the most common 
screening procedure used to evaluate patients with suspected PE. With this 
technique, a 5 or 7.5MHz linear array probe is used to compress the veins at 
1-cm intervals between the proximal portion of the common femoral vein to 
the trifurcation of the popliteal vein distal to the popliteal fossa. The absence 
of vein compressibility is the most sensitive and specific feature of deep vein 
thrombosis (DVT). Doppler flow and colour doppler are used to assist with the 
identification of veins but do not appear to otherwise add to the diagnostic 
accuracy of the technique.65 
 
In the past venography has been regarded as the gold standard for the 
diagnosis of DVT. It was and is the most reliable test for identifying 
thrombosis in isolated to calf veins. However, with the advent of 
ultrasonography, its use is largely of historical interest only. Venography 
detected the presence of DVT of the lower extremities in 70% to 90% of 
patients with PE with most thrombi found in the proximal leg veins.66-68 66,67,68 
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With the use of bilateral compression ultrasonography of the proximal venous 
system, significantly fewer deep vein thrombi are detected in patients with PE 
than with venography. Only 25% to 50% of patients with PE will be found to 
have deep vein thrombosis when ultrasonography is used as a screening 
test.69-72 69,70,71,72Most of these thrombi will be asymptomatic. These lower sensitivity 
figures likely reflect the limitations of ultrasound as a screening test for DVT in 
asymptomatic patients. If both thrombo-embolic risk factors and symptoms of 
DVT are absent, the usefulness of ultrasonography in patients with an 
indeterminate- or low-probability scan is low.73 Although thrombo-embolic risk 
factors or symptoms of DVT are present in nearly 70% of patients with 
suspected PE, the prevalence of DVT in that group has been reported to be 
6% and 8% in two studies.3,73,74 
 
Compression ultrasonography is a very accurate test for the diagnosis of 
proximal DVT of the lower extremities in symptomatic patients presenting with 
their first suspected episode. In this setting, compression ultrasound has been 
shown to have a sensitivity and specificity of approximately 97%.75 Ultrasound 
is less sensitive and specific as a diagnostic test for DVT isolated to calf 
veins.75 Many centres do not routinely image calf veins because of this lack of 
accuracy, it is time consuming and, the fact that isolated calf clots have a 
relatively low risk of developing into PE in the absence of their extension into 
the more proximal venous system.2 Specialized training and additional 
procedure time were required for a complete calf vein assessment.76 
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In a search for safe, non-invasive strategies for the investigation of suspected 
pulmonary embolism, it has been recommended that ultrasonography be 
performed as an alternative to pulmonary angiography in patients with non-
diagnostic V/Q scans to look for evidence of DVT.58,77,78 Multiple studies have 
reported that the outcome of patients presenting with symptoms of suspected 
DVT is excellent as long as ultrasonography at the proximal venous system 
(popliteal to common femoral vein) remains negative.78-80 79,80,About 1% of 
patients in whom a diagnosis of PE is excluded and who are not managed 
with anticoagulant therapy, will subsequently return with DVT or PE in follow-
up.5,81-85 81,82,83,84,85This complication rate is similar to the development of PE in the 
follow-up of patients with normal pulmonary angiograms.86 
 
The performance of ultrasonography as the initial diagnostic test in clinical 
situations can be argued where pulmonary imaging is relatively 
contraindicated or problematic to perform. Such settings would include 
pregnant patients in whom radiation exposure is undesirable or in critically ill 
patients in whom transport to radiology departments is problematic.  
With more recent research advances such as the development of clinical 
probability scores and D-dimer, the need for serial ultrasonography can be 
avoided.82,87-89 87,88,89 
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IMAGING – (involving radiation) 
Chest Radiography 
A chest radiograph remains important in all patients for the exclusion of 
alternative readily diagnosable conditions (pulmonary edema, pneumonia, 
fractures, pneumothorax, COPD, lung cancer or pulmonary fibrosis) and to aid 
in interpretation of subsequent tests.90 
 
A routine chest radiograph obtained in both the posterior-anterior and lateral 
projections is preferred. A portable anterior-posterior chest radiograph is 
acceptable only if the patient cannot tolerate a routine chest radiographic 
examination. In patients who have no changes in signs or symptoms, a chest 
radiograph within 1 day of scintigraphy is adequate. A more recent chest 
radiograph (preferably within 1 hr) is necessary in patients whose signs and 
symptoms are changing.91 
 
A chest radiograph plays a major role in the choice of subsequent imaging 
tests (V/Q scintigraphy or CTPA). It has been shown that the presence of any 
abnormality on the initial chest radiograph decreases the utility of V/Q 
scintigraphy.92 Conversely, a normal recent chest radiograph strongly 
indicates that scintigraphy will have a high likelihood of confirming or refuting 
the diagnosis of PE. Patients with no underlying cardio-respiratory disease or 
with (near) normal chest radiographs can safely undergo V/Q scanning 
because the diagnostic yield will be much higher than in an unselected group  
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(definite diagnoses are obtained in well above 80%).93 In some diagnostic 
algorithms it also defines the requirements for ventilation scintigraphy and is 
pivotal in the interpretation of the perfusion scintigram. Normal radiographs 
have been described in at least 12 – 30% of patients with PE.4,40,90 
Radiological signs of PE on a chest x-ray include Fleischner’s sign – dilatation 
of the proximal pulmonary artery; Hampton’s hump – pleural based infiltrates; 
Westermark’s sign – decreased vascularity ipsilateral to the PE affected 
area.94 Atelectasis, a raised hemidiaphragm, cardiomegaly and pulmonary 
infarction may also be seen. However, while these chest X-ray findings raise 
suspicion of PE, they are not diagnostic of PE.13 
 
The original PIOPED study had a very high number of inpatients who 
constituted 68% of the total population. PIOPED II had an inpatient population 
of 11%. Inpatients are much more likely to have abnormalities on chest 
radiographs that would potentially interfere with optimal V/Q scan 
interpretation. Screening patients by chest radiography has significantly cut 
down the number of intermediate, non-diagnostic interpretations in V/Q 
scans.4,40 
 
Computed Tomography (CT) 
In 1982, Sinner and coworkers95 reported abnormalities within the first (main) 
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through third (lobar) order pulmonary arteries with central emboli using non-
helical (non-spiral) CT in the first series of 21 consecutive patients with 
clinically suspected PE. During the next decade, most reports on the use of 
CT for PE described the appearance of PE on non-helical CT scans obtained 
for other reasons where PE was an incidental finding or on the use of CT for 
massive or central PE. In 1992, Remy-Jardin and coworkers first reported the 
use of helical (spiral) CT for the evaluation of central PE in 42 patients, using 
selective pulmonary angiography as the reference test, demonstrating 100% 
sensitivity and 96% specificity.96 As with many first reports, the accuracy 
estimates may have been high because of the selection of more ideal patients 
for study (selection bias). Helical CT quickly evolved from being performed on 
single detector scanners to multi-detector scanners. 
 
For single-detector helical CT, sensitivity and specificity in the detection of PE 
have been reported to vary from 53% to 91% and from 78% to 97%, 
respectively.97 
 
Catheter Pulmonary Angiography 
Using angiography, PE is diagnosed based on direct visualization of 
endoluminal filling defects, thromboemboli, or abrupt vascular obstruction. 
Indirect signs, such as delayed opacification or a diminished capillary stain, 
 
 - 31 - 
 
 
are nonspecific. Atelectasis is a common finding; it is shown as crowding of 
the vessels, usually at the lung bases. Findings in chronic PE include arterial 
webs, stenoses, irregular occlusions, scalloped mural irregularities, and the 
pouching defect (a concave edge of thrombus facing the opacified lumen).98,99 
 
Since the late 1960s, catheter pulmonary angiography has been considered 
the most accurate test or gold standard for the evaluation of PE and the 
reference test to which new diagnostic techniques are compared.100,101 
However, catheter pulmonary angiography is invasive, with a 2% morbidity 
and small risk of mortality, which have contributed to its under utilization.102,103 
The method is time consuming and labour intensive, and it requires the use of 
a relatively large amount of contrast material. Currently, conventional or cut-
film angiography is rarely used, which have been surpassed by digital 
subtraction pulmonary angiography (DSPA) which can be performed rapidly 
and safely with minimal discomfort to the patient.104 
 
DSPA is the criterion standard or definitive test in evaluating diseases 
involving the pulmonary vasculature including PE. The technique allows 
visualization of all pulmonary arterial branches, catheter-based measurement 
of pulmonary artery pressure, and may be used for therapeutic interventions 
e.g. catheter-directed thrombo-fragmentation and embolectomy for PE.104 
 
The DSPA technique requires percutaneous venous catheterization, 
intracardiac catheter manipulation and catheterization of the pulmonary artery.
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Ionizing radiation and iodinated contrast agents are used to produce images 
of the pulmonary arteries and veins. The right common femoral vein is the 
vessel most commonly used. The jugular or an upper-arm vein may also be 
used. The injection is preferably made within each of the main pulmonary 
arterial branches and is positioned so as to allow all of the lobes of one lung 
to be well opacified. Rapid-sequence images are acquired in multiple antero-
posterior and oblique projections. A major concern is the passage of the 
catheter through the heart with the possible induction of cardiac 
arrhythmias.104 
 
Significant variation in inter-observer agreement related to embolus size has 
been observed for pulmonary angiography. In the PIOPED study, the 
interobserver agreement on the presence or absence of subsegmental PE 
was found to be 66% as compared with 98% and 90% in relation to lobar and 
segmental PE, respectively. This suggests that subsegmental PE may be 
difficult to diagnose even using pulmonary angiography, and that 
subsegmental PE may have been missed. Therefore pulmonary angiography 
may not be an adequate gold standard for PE diagnosis.14,86 
 
Computed Tomography Pulmonary Angiography (CTPA) 
Multi-detector Computed Tomography (MDCT) scanners with 4, 8, 16, 32, and 
64 detector-rows are now several years old and have solved most of the 
problems concerning single-slice CT angiography. 
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The collimation or slice thickness used today is commonly at or near 1-mm, 
with sub-second gantry rotation speeds of 0.3 to 0.5 seconds resulting in 
improved spatial and temporal resolution as well as increasing the number of 
subsegmental (fourth-order pulmonary arterial branches and smaller) arteries 
that can be evaluated, enhancing the interpretation of the spiral CT scan105,106 
and improving observer agreement.107 The increased number of detectors 
means that a greater craniocaudal thickness of the thorax is included in each 
gantry rotation; hence, more detectors means faster scanning. Scan times 
range from 18 to 28 seconds on 4-MDCT, 8 to 13 seconds on 16-row MDCT, 
and 4 to 6 seconds on 64-MDCT. These scan times allow high-resolution 
imaging of small pulmonary arteries throughout the entire thorax in a single 
breath-hold even in dyspnoeic patients.108 Soon scanners with an even 
greater number of detector row systems will become more widespread and 
there is even the possibility of a volume CT scanner that would allow imaging 
of the entire thorax in a single gantry rotation.109 
 
During the past decade, many centres have adopted CTPA as the pulmonary 
imaging procedure of choice for patients with suspected pulmonary 
embolism.110 CTPA has an intuitive appeal for clinicians because it provides 
dichotomous or binary results (either positive or negative), the thrombosis is 
directly visualized in the pulmonary arterial circulation, permits multi-planar 
reconstruction, alternative causes for symptoms may be observed and  
widespread availability especially outside routine hours.110 
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CT is able to depict other conditions better than V/Q scintigraphy, pulmonary 
angiography, and MR angiography.109 CT can also demonstrate other 
conditions that clinically mimic PE, such as acute pneumonia, lung abscess, 
pneumothorax, pneumomediastinum, pleural or pericardial effusion, aortic 
dissection, cardiovascular disease, mediastinitis, mediastinal abscess, 
esophageal rupture, malignancy and interstitial pulmonary fibrosis. In addition, 
64-detector scanners have the ability to detect coronary artery disease during 
the same study, if the appropriate parameters are set. Such disorders have 
been reported in 11% to 70% of CT examinations performed for suspected 
acute PE.112-117 111, 112, 113, 114, 115, 116 
 
PIOPED II is the largest and most significant study that assessed the use of 
MDCT in the diagnosis of PE. Positive predictive values (PPV) were 96% with 
a concordantly high probability of VTE on clinical assessment, 92% with an 
intermediate probability on clinical assessment and 58% or non-diagnostic if 
clinical probability was discordant. Negative predictive values (NPV) in the 
PIOPED II study were 96% with a concordantly low probability of VTE on 
clinical assessment, 89% with an intermediate probability on clinical 
assessment and 60% or non-diagnostic if clinical probability was discordant.40 
 
On a per-patient basis, CTPA interobserver agreement for the detection of 
acute PE is moderate to almost perfect, with kappa values ranging from 0.59 
to 0.94.109  
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Computed Tomography Venography (CTV) 
Since PE is believed to originate from the lower extremities or pelvis, CT 
venography is an important adjunctive tool in the protocol of PE evaluation at 
the time of CTPA. 
 
Investigators have evaluated whether CT venography of the proximal venous 
system could be performed during CTPA to diagnose deep vein thrombosis 
and potentially avoid the need to perform ultrasonography. Studies have 
demonstrated that it is technically feasible to perform CTPA and CT 
venography during the same procedure. Furthermore, combining the two, 
modestly increased the diagnostic yield of venous thromboembolism.117,118 
 
In PIOPED II, the sensitivity of CTPA for PE was 83% and specificity 96%. In 
subjects where CTV was also performed, the combined sensitivity for PE and 
DVT was 90% and the specificity 95%. However, there are concerns about 
the routine performance of CT venography because of its high contrast load 
and additional radiation exposure. During the course of PIOPED III, data 
analyzed from PIOPED II showed that venous phase CT venography and 
venous ultrasound were diagnostically equivalent.119 
 
Magnetic resonance angiography/ venography (MRA/MRV) 
Magnetic resonance (MR) has not yet found a routine role in the imaging of 
patients with suspected PE and is still at an early stage of development. It has  
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the ability to image vascular structures without ionizing radiation or iodinated 
contrast but utilizes gadolinium based contrast and can also indicate 
alternative diagnoses. Currently, gradient-echo and spin-echo MR techniques 
are used, with faster imaging sequences and gradients that allow imaging the 
entire chest in a single breath hold. MR may play a role in PE diagnosis in 
future.120 
 
Previous investigations of gadolinium-enhanced MRA(Gd-MRA) showed a 
sensitivity that ranged from 77% to 100% in studies of 8 to 35 patients with PE 
and specificity ranged from 95% to 98% among 22 to 83 patients in whom PE 
was excluded.121-123 121,122,123More recently, one study reported sensitivities that 
differed considerably between readings by teams of experienced radiologists. 
Among 63 patients with PE, sensitivities were 31% with readings by outside 
radiologists and 71% with readings by local radiologists. Specificities among 
26 patients who did not have PE were 85% and 92%, respectively.124 
 
However, there are many pitfalls to MRI which include patient isolation and 
the examination duration with the need for an extended breath hold potentially 
limits its use in unstable or critically ill patients. In addition, image degradation 
resulting from breathing artefacts and areas of atelectasis, perihilar or 
peribronchial fat have been misinterpreted as PE.125 There are concerns with 
regard to nephrogenic systemic fibrosis/ nephrogenic fibrosing dermopathy 
(NSF/NFD), which occurs rarely in patients with poor renal function who  
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receive gadolinium-containing contrast material. Therefore, similar to CTPA, 
gadolinium-enhanced MRA is contraindicated in patients with impaired renal  
function and also a history of allergy to gadolinium-containing contrast agents 
or to iodinated contrast media (since patients allergic to iodinated contrast 
material are sometimes allergic to gadolinium containing contrast media).126 
 
The PIOPED III trial was designed to study the accuracy of gadolinium-
enhanced MRA in combination with venous phase magnetic resonance 
venography(MRV) for the diagnosis of acute PE. Although recently 
completed, the results are not yet available. However, the investigators have 
published an article describing the methods used in the study. Total scan time 
for Gd-MRA was 20 minutes while for gadolinium-enhanced MRV was 
approximately 3 minutes. Gd-MRA diagnostic criteria for acute PE were 
partially occlusive intra-luminal filling – seen as “railway tracking,” i.e. a small 
amount of contrast material between the central filling defect and the arterial 
wall. In cross sectional images, PE are seen as filling defects surrounded by  
contrast material and/or complete arterial occlusion with termination of the 
column of contrast material in a meniscus that outlines the trailing edge of the 
embolus. The diagnostic criteria for acute DVT on Gd-MRV were occlusive – 
a complete filling defect, i.e., failure to opacify the entire lumen due to a 
central filling defect (the vessel may enlarge compared with the opposite vein) 
and/or non-occlusive – a partial filling defect surrounded by opacification.127 
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LUNG SCINTIGRAPHY 
A ventilation (V) and perfusion (Q) scan is often referred to as a V/Q scan. It 
was introduced in 1964 for the evaluation of pulmonary blood flow and has 
been used as the first-line examination for patients with suspected PE for 
several decades.128 
 
V/Q scintigraphy is a diagnostic radionuclide imaging test that assesses both 
pulmonary perfusion (arterial flow) using limited capillary blockade as well as 
ventilation using inhaled inert gases or aerosols by recording their distribution 
using a gamma camera acquisition either by two-dimensional (2D) planar 
imaging or three-dimensional (3D) SPECT imaging.91,129 
 
Conventional interpretation of V/Q scintigraphy is based on two-dimensional 
(2D) planar image acquisition.129 With very few exceptions (such as central, 
non-obstructing PE causing an evenly distributed reduction in whole lung 
perfusion, or minimal perfusion defects below the resolution power of 
scintigraphy), a normal perfusion scan virtually excludes the diagnosis of 
PE.101 
 
The V/Q scan has decreased radiation and the advantage of not requiring 
iodinated contrast material, unlike CTPA. Therefore, if a patient with 
suspected PE has a history of an iodinated contrast allergy or renal 
impairment, V/Q scintigraphy is recommended as an alternate test to CTPA. 
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V/Q scintigraphy is also recommended when obesity (increased body mass 
index [BMI]) prevents a patient from either fitting into the CT gantry or is 
beyond the weight limit for the CT and/or angiography table.109 
 
V/Q scanning has been the imaging procedure of choice in patients with 
suspected PE especially in those with a normal chest radiograph. A normal 
V/Q scan essentially excludes the diagnosis of PE (1% VTE rate in follow-up), 
while a high-probability lung scan has an 85% to 90% positive predictive value 
for PE.4,68 Unfortunately, most planar V/Q scans fit into a non-diagnostic 
category, in which the incidence of PE varies from 10% to 30% and further 
investigation is necessary.4,5 However, physicians should be not deceived that 
CTPA is the holy grail because a recent meta-analysis130 suggests that the 
sensitivity and the specificity of CTPA is 86% and 93.7%, respectively. 
 
In a retrospective study on PE in pregnant patients, lung scintigraphy proved 
to be a more reliable imaging technique for the diagnosis or exclusion of PE 
than did pulmonary CTPA (p=0.0058). This is because of interruption of 
contrast material by unopacified blood from the inferior vena cava during 
CTPA. It was recommended that lung scintigraphy should be the technique of 
choice for imaging of pregnant patients with suspected PE unless the image 
quality of pulmonary CTPA can be optimized with adapted breathing 
maneuvers and contrast administration.17 
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V/Q scintigraphy has been shown to have higher sensitivity (94% – 97.4%) 
than multidetector CT pulmonary angiography (51%) in detecting chronic 
thrombo-embolic pulmonary disease as a treatable cause of pulmonary 
hypertension.131 
 
The PIOPED II study focused on the accuracy of CTPA rather than comparing 
its accuracy with V/Q imaging.40 In fact, the V/Q scan actually represented the 
most frequently used reference standard required for entry into the study. The 
overall sensitivity and specificity of CTPA in the 824 patients studied was 83% 
and 96% respectively, after 6% (51 patients) of the study population were 
excluded due to technical inadequacy. With the entire study population 
included, the overall sensitivity and specificity of CTPA declined to 78% and 
90%, respectively. The overall positive predictive value (PPV) of 86% and 
negative predictive value (NPV) of 95% are values comparable to V/Q 
statistics.132,133 
 
One of the major parameters in judging the effectiveness of a diagnostic 
procedure is examining the rate of false negatives (FN). In patients with 
suspected PE and negative imaging, a subsequent diagnosis of PE or deep 
vein thrombosis (DVT) within 3 months constitutes a reasonable FN. Results 
from two recent studies support the comparable FN rate of V/Q scintigraphy 
and CTPA. In a large, prospective randomized Canadian study in more than 
1,400 patients with high pretest probability and/or positive D-dimer levels, 
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the FN rates for V/Q scintigraphy and CTPA were similar at 1% and 0.4%, 
respectively.81 In another study of over 2,000 patients, the FN rates were 
statistically equivalent at 1.1% for V/Q scans and 1.2% for CTPA when the 
chest radiograph was used to guide the choice of procedure.134 
 
Anderson et al81 showed that more emboli were detected by CTPA than by 
V/Q scintigraphy but questioned the clinical significance of detecting and 
treating these smaller emboli. Although not proven, it is believed that the 
pulmonary capillary bed traps small emboli and prevents them from entering 
the systemic circulation, possibly even in normal individuals.135 Nielsen et al136 
randomized patients with DVT to either anticoagulation or a non-steroidal anti-
inflammatory agent (NSAID). In each group, 50% developed PE and it was 
concluded that anticoagulant therapy had no effect on disease progression. 
The burden of clot has prognostic significance and may be a major 
determinant of whether anticoagulant therapy is appropriate. Patients with 
underlying cardiopulmonary disease who develop even small PE are at 
greater risk of developing right heart failure, death and chronic pulmonary 
hypertension137 and should be anticoagulated. V/Q studies are sometimes 
requested in pulmonary hypertension patients to evaluate for chronic PE. If 
present, chronic PE is treated with anticoagulation to prevent disease 
progression.138,139 
 
Goodman135,140 recently defined several patient groups where the risks of  
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anticoagulant therapy may outweigh the benefits. Freeman and Haramati138 
recommended that further prospective, controlled studies are needed to 
resolve this problem. 
 
A) V/Q Planar 
V/Q Planar scintigraphy is a standard investigation for the diagnosis of 
pulmonary embolism. A V/Q planar scan is comparable to a standard chest X-
ray in terms of two-dimensional (2D) imaging. 
 
Although widely used for over 30 years in the assessment of pulmonary 
embolism (PE), V/Q Planar scintigraphy is hampered by the inherent 
limitations of 2D imaging. These include significant overlap of anatomical 
segments, ‘shine-through’ from underlying lung segments with normal 
perfusion, and difficulty in visualizing all of the lung segments, especially the 
medial basal segment of the right lower lobe.141 For referring clinicians, 
accurately confirming or excluding PE is essential. The use of probabilistic 
reporting schema, which is widespread following the PIOPED study, is a 
significant limitation of planar imaging and has eroded clinician confidence in 
V/Q scanning, due primarily to the perception that many studies are non-
diagnostic.142 
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B) V/Q SPECT  
The principles of single photon emission computed tomography (SPECT) 
imaging are based on emission tomography which provides three dimensional 
(3D), quantitative images of the radiotracer distribution used to mark 
physiological, metabolic, or pathological processes. SPECT is comparable to 
computed tomography (CT) in terms of 3D acquisition. SPECT allows 
simultaneous imaging of more than one process, e.g. both regional blood flow 
and ventilation during normal tidal breathing – no breathing manoeuvre 
required – for the whole lung. Quantitative single photon emission computed 
tomography (SPECT) requires correction for the image degrading effects due 
to photon attenuation and scatter.143 
 
V/Q Planar vs. V/Q SPECT 
Studies performed in animal models and in clinical practice have consistently 
shown that the use of V/Q SPECT will increase both sensitivity (from 64-71% 
to 91-100%) and specificity (from 79-91% to 87-100%) compared with planar 
imaging.144 In addition, several studies have also shown that V/Q SPECT 
improves intraobserver and interobserver reproducibility148,145,146 and results in 
an extremely high negative predictive value of 98.5% and a low indeterminate 
rate in one large prospective series.147 SPECT has also been shown to reduce 
the number of intermediate or inconclusive results (the Achilles’ heel of planar 
V/Q scintigraphy) to less than 5%.147 
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Only about 50 – 80% of cases can be resolved by planar scintigraphy.148 In 
one study by Collart et al148, a total of 114 consecutive patients with a 
suspected PE underwent planar and SPECT lung 99mTc MAA perfusion scans 
as well as planar 81mKr ventilation scans. The final diagnosis was obtained by 
using an algorithm, including D-dimer measurement, leg ultrasonography, a 
V/Q scan and chest spiral computed tomography, as well as the patient 
outcome. A planar perfusion scan was considered positive for PE in the 
presence of one or more wedge shaped defect, while SPECT was considered 
positive with one or more wedge shaped defect with sharp borders, three-
plane visualization, whatever the photopenia. Intraobserver and interobserver 
reproducibilities were 91% / 94% and 79% / 88% for planar / SPECT images, 
respectively.148 The sensitivities for PE diagnosis were similar for planar and 
SPECT perfusion scans (80%), whereas SPECT had a higher specificity (96% 
vs 78%; p=0.01). SPECT correctly classified 8/9 intermediate and 31/32 low 
probability V/Q scans as negative.148 It was concluded that lung perfusion 
SPECT is readily performed and reproducible. A negative perfusion SPECT 
study eliminates the need for a combined V/Q study and most of the `non-
diagnostic' V/Q probabilities can be solved with a perfusion image obtained by 
using tomography.148 
 
Bajc et al146, in a prospective study of 53 patients suspected for PE, evaluated 
whether the diagnostic information of V/Q SPECT applied in clinical routine 
might enhance information compared with V/Q planars and streamline data - 
 
 - 45 - 
 
 
processing for the demands of clinical routine. After inhalation of 99mTc DTPA, 
planar ventilation imaging was followed by tomography, using a dual-head 
gamma camera. 99mTc MAA was injected for perfusion tomography followed 
by planar imaging. Patients were examined in the supine position, unchanged 
during V/Q tomography. Two reviewers evaluated V/Q planar and V/Q SPECT 
images separately and randomly. Mismatch points were calculated on the 
basis of extension of perfusion defects with preserved ventilation. Patients 
were followed up clinically for at least 6 months. With V/Q SPECT the number 
of patients with PE was higher and 53% more mismatch points were found. 
Ancillary findings were observed by both techniques in half of the patients but 
more precisely interpreted with V/Q SPECT. V/Q SPECT showed more and 
better delineated mismatched defects, improved quantification and less 
interobserver variation compared with V/Q planars. It was concluded that V/Q 
SPECT is amenable to implementation for clinical routine and suitable even 
when there is demand for a high patient throughput.146 
 
V/Q SPECT not only increases the diagnostic accuracy of the method but also 
permits the application of advanced image-processing techniques. With the 
help of these techniques, the detection of matched and mismatched defects 
can be automated and objectified. In comparison with conventional (visual) 
image interpretation, the automated analysis leads to significant improvement 
in detection rate of pathological lesions. As far as sensitivity is concerned,  
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the computerized procedure proved to be excellent, especially in complex 
cases with heterogeneous ventilation and perfusion. Yet it could not surpass 
the accuracy of conventional image interpretation, primarily because of 
artefacts in the pulmonary recesses. If these artefacts could be overcome, the 
efficiency of the automated algorithm would be at least equivalent to that of the 
conventional approach. At present, the best results can be achieved by 
combining both the automated analysis and conventional evaluation.149 
 
The incremental value of tomography (SPECT) over planar studies was 
evaluated in another study. There was marked improvement in the accuracy 
of determination of defect size for tomographic studies over the planar 
equivalents. With planar studies, the accuracy of estimation of defect size was 
51% compared with 97% using tomographic studies in the computerized 
model of PE. Defects in the medial basal segment of the right lower lobe were 
not identified in planar studies but were easily seen by all observers in the 
tomographic study. This was especially important in the lung bases, the most 
common reported site of pulmonary emboli.150 
 
A further option in V/Q SPECT is to calculate and display ventilation/perfusion 
quotient (V/Q quotient) images using standard software. Based upon 
acquisition in which the patient is examined without movement between 
ventilation and perfusion imaging, the ventilation background may be 
subtracted from perfusion tomograms.151 After normalization of the ventilation  
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to perfusion count rates, a V/Q quotient is calculated. The V/Q quotient 
images facilitate diagnosis and quantification of PE extension, particularly in 
complex cases. Notably, as attenuation is similar for ventilation and perfusion 
studies, V/Q quotient images make attenuation correction less important.42 
 
Palmer et al151, developed a fast method for V/Q SPECT to improve 
diagnostic value of lung scintigraphy, using 99mTc DTPA aerosol and 99mTc 
MAA for ventilation and perfusion respectively on 15 patients. Total SPECT 
acquisition was 20 min. 99mTc DTPA clearance, calculated from initial and final 
ventilation SPECT projections was used for correction of the ventilation 
projection set before iterative reconstruction of V/Q SPECT data. The 
ventilation background was subtracted from perfusion tomograms. A 
normalized V/Q quotient was calculated. V/Q SPECT had adequate quality 
and showed V/Q quotient relationships more clearly than did planar images. 
Frontal and sagittal slices were superior than planar scintigraphy in 
characterization of embolized areas. It was deduced that fast, high flying V/Q 
SPECT is possible, more comprehensive and has higher objectivity in 
evaluating PE; costs for the procedure seemed low.151 
 
Based on the premise that PE results in the lung is altered to a number of 
distinct functional subpopulations, Harris et al152 evaluated a novel parameter 
of V/Q heterogeneity, termed the “weighted median V/Q value” and found it to 
be the most accurate parameter with respect to PE diagnosis. 
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Such objective analysis of V/Q SPECT may reduce the number of non-
diagnostic scintigraphy results by providing quantitative measures of V/Q 
mismatch and more likely may be useful in the physiological investigation of 
other pulmonary diseases. V/Q SPECT has the definite advantages of being 
better able to quantify the extent of perfusion abnormalities (which may be 
valuable in guiding treatment decisions) and can assess reperfusion after PE 
(especially in follow up), something not easily done with CTPA.141,146 
 
Harris et al129, compared interpretation of traditional planar ventilation–
perfusion lung scan images with planar images reformatted from SPECT data 
using two different techniques. V/Q data were acquired from 50 patients 
referred with suspected pulmonary embolism. In addition to traditional six-
view planar images, six-view planar images were also generated from SPECT 
data using two methodologies: an angular summing technique (angular 
summed planar images) and a forward projection technique (reprojected 
planar images). Three experienced nuclear medicine clinicians reviewed the 
images in a blinded, randomized fashion. Results were analyzed by 
comparing the two reprojected techniques with the traditional true planar 
scans, examining for differences in the defects seen (number, type and 
confidence), and the impact on final clinical interpretation. Compared with true 
planar scintigraphy, angular summed images demonstrated fewer 
mismatched defects (p<0.0001), while the reprojected planar images had 
more matched defects (p=0.013). In addition, there was a significant change  
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in the clinical interpretation of the angular summed planar images resulting in 
clinicians perceiving a decreased likelihood of pulmonary embolism (p<0.016). 
No such difference in interpretation was observed for the reprojected planar 
images. It was concluded that angular summed planar images result in a 
perceived decreased likelihood of pulmonary embolism compared with true 
planar images. In contrast, while reprojected planar images resulted in an 
increased number of matched defects compared to true planar scans, there 
was no change in the clinical interpretation.129 
 
Based on the available evidence, Roach et al, proposed that V/Q SPECT 
scans be used as the initial diagnostic test in cases of suspected PE and have 
considerably less radiation exposure (particularly to the breast) than CTPAs. 
V/Q SPECT should be performed using state-of-the-art technology. This 
includes a superior ventilation agent, a modern generation multi-headed 
gamma camera, and a software display package that allows co-registered 
ventilation and perfusion scans to be viewed simultaneously in the three 
orthogonal planes in a synchronized manner. V/Q SPECT is a new paradigm 
and, as such, probabilistic reporting criteria such as the PIOPED scheme 
should be discarded. The applicability of PIOPED criteria (derived from a 
single view 133Xe planar image or multi-view planar perfusion scans) to V/Q 
SPECT is dubious. Lung scanning has advanced since that time and new and 
more appropriate reporting schema should be used.9 
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Currently, debate remains regarding the appropriateness of performing V/Q 
scintigraphy or CTPA as the initial imaging procedure for suspected PE. 
According to Roach et al9, direct comparisons of the two techniques are 
limited and a published prospective study showed that V/Q SPECT was more 
sensitive, but less specific than multidetector CTPA, with comparable overall 
accuracy.145 A multicenter prospective trial is ideal to answer this question, 
but is difficult for several reasons: 
a) Evaluating the clinical effectiveness of rapidly evolving health 
technologies is problematic. Both CT and V/Q SPECT technology 
continue to develop and, therefore, any published direct comparison 
inevitably reports on previous-generation technology. 
b) A robust ‘gold standard’ is lacking for the diagnosis of PE resulting 
in the V/Q scan and/or CTPA being pivotal in determining the 
presence or absence of disease142,146 
c) Ethical concern about subjecting individuals to the radiation 
exposure from both V/Q SPECT and CTPA, especially in individuals 
without PE.  
d) The time interval between the two studies being performed could 
result in embolus fragmentation, movement, or lysis, thus affecting 
the perceived accuracy of each modality. 
 
Given the superiority of V/Q SPECT over planar imaging and the various 
limitations of CTPA, the use of V/Q SPECT remains limited due to;  
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a) CTPA is widely available and is often more accessible than V/Q 
scanning.141 
b) Reporting specialists may be reluctant to change to SPECT given 
their familiarity with planar imaging and lack of familiarity with 3D 
lung anatomy. However, SPECT data can be used to easily 
generate planar-like images that may be helpful during a transition 
period to SPECT.153 
c) The misconception that SPECT imaging takes longer to acquire 
than traditional planar imaging. With the use of multi-head gamma 
cameras and modern computing, SPECT acquisition times are 
often faster than typical planar studies.9 
d) There may be the belief that SPECT can only be performed with 
ideal ventilation agents, such as Technegas. Several other 
satisfactory options are available for ventilation SPECT imaging, 
including several new generation radioaerosol nebulizers using 
99mTc-DTPA. Inert radioactive gases such as 81mKr can be used, 
although often less readily available and relatively expensive. The 
ongoing use of 133Xe as the primary ventilation agent in many 
centers in the United States is certainly a factor hampering the 
development of V/Q SPECT in that country.9 
These two modalities (V/Q SPECT and CTPA) have complementary roles and it is 
important that clinicians recognize the strengths and weaknesses of each (Table 3) 
so that the appropriate test can be selected in individual patients.9 
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Table 3 Strength and weaknesses of CTPA and Lung Scintigraphy in PE45 
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Radiopharmaceuticals used in Lung Scintigraphy 
(i.) Perfusion Imaging Agent 
Technetium-99m macroaggregates of albumin (99mTc MAA) is the radio-
pharmaceutical of choice for pulmonary perfusion imaging. Its mechanism of 
localization is by capillary blockade. In normal circumstances, more than 90% 
of the particles (>10µm) are mechanically trapped in the lung capillaries within 
5 to 10 minutes, depending on the regional pulmonary blood flow. Optimally, 
between 100,000 and 400,000 particles are required to allow good statistical 
distribution.10,11,154,155 
 
Production of MAA particles is by heat aggregation of human serum albumin 
(HSA) with a reducing agent (stannous chloride) in buffer (acetate) at 80-900C 
for 30 minutes. The particles are then washed with normal saline to remove 
any free stannous ions, re-suspended in saline and aliqouted in vials to be 
used later in kits. Commercial kits are available in lyophilized form. Different 
manufacturers add other inactive ingredients such as sodium acetate, HSA, 
succinic acid and lactose to facilitate particle dispersion during reconstitution 
with pertechnetate. The number of particles varies from 1 to 12 million 
particles per milligram of MAA. The labelling efficiency should be greater than 
90%. Microscopic inspection on hematocytometer (grid size = 50m) should 
be performed to make sure that the MAA particles are not too large (should 
not exceed 100µm) or clumped. The particle size of MAA generally ranges 
from 5 to 100µm, with above 60% in the range of 10 to 60µm.10,11,154,155 
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After intravenous injection through a peripheral vein, the 99mTc MAA particles 
travel intravascularly to be trapped in the pulmonary bed via the right atrium 
and ventricle. The number of capillaries occluded is negligible (less than 0.1% 
of about 280 billion capillaries). 99mTc MAA has a biological life of 2 to 3 hours. 
It may begin to breakdown even as early as 30 minutes after injection 
depending on the kit used. The particles are broken down into smaller 
particles by mechanical movement of the lung during breathing and/or through 
enzymatic proteolysis. The broken down particle fragments (<10µm) enter the 
systemic circulation to be removed by phagocytes of the reticuloendothelial 
system.10,11,154,155 
 
The recommended administered activity in adults (70kg body mass) is 
between 74 to 148MBq containing 200,000 to 350,000 MAA particles. The 
lung is the critical organ receiving an absorbed dose of 5mGy for a 111MBq 
99mTc MAA dose. Contraindications to radionuclide particulate lung perfusion 
scans include severe pulmonary hypertension (can cause a sudden rise in 
pulmonary pressure and even death) and a history of hypersensitivity 
reactions to products containing human serum albumin. Caution should also 
be exercised in patients with known right to left shunts to avoid adverse 
effects leading to coronary or cerebral microembolization. Hypersensitivity 
reactions to products containing HSA are possible, thus epinephrine, 
antihistamines and corticosteroids should be available.10,11,154,155 
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(ii.) Ventilation Imaging Agents 
Ventilation imaging agents used in radionuclide lung scans include radioactive 
inert gases such as Xenon-133 (133Xe) and Krypton-81m (81mKr), radio-
labelled aerosols such as 99mTc-diethylenetriaminepentaacetic acid (DTPA) 
and Technegas. 
a) Xenon-133(133Xe) 
Xenon-133 gas has a half life of 5.3 days with 81keV principal gamma 
ray energy. The low energy leads to attenuation of the gamma rays 
and is the reason for the single projection posterior positioning during 
ventilation imaging. The patient is asked to inhale 133Xe (10-15mCi or 
370-555MBq) gas mixed with air in a closed system. The critical 
structure is the trachea. 133Xe allows assessment of all phases of 
regional ventilation using initial single breath, wash-in or equilibrium 
and washout acquisition. The initial single breath phase represents 
instant ventilation, wash-in and equilibrium phases are proportional to 
the aerated lung volume while the washout phase demonstrates 
regional clearance or areas of air trapping. 133Xe is usually 
administered by using one of the commercially available delivery and 
rebreathing units. 133Xe gas is heavier than air, thus, when exhaled it 
can be released to the environment via an exhaust vent at ground 
level. A charcoal trap may be used or the study may be performed in a 
room kept under negative pressure.10,11,154 
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b) Krypton-81m (81mKr) 
Krypton-81m gas has a half life of 13 seconds with 190keV as the 
principal gamma ray energy. It is eluted from a Rubidium 81 (81Rb) 
generator which has a half life of 4.6 hours implying that it can be used 
for 1 day. Unlike 133Xe, 81mKr is used in a continuous steady-state 
inhalation technique that is proportional to the regional ventilation rate 
rather than lung volume. 81mKr, by virtue of its radio-physical 
characteristics is often considered a reference gas for ventilation 
scintigraphy. Its short half-life (13s) enables multiple views and leads to 
a low radiation exposure. This makes 81mKr suitable for use in 
children156 and pregnancy. The high photon energy (190 keV) allows 
simultaneous or immediate acquisition of perfusion and ventilation data 
in multiple and comparable views. Consequently, a short time is 
required for the procedure and, because 81mKr has a short half-life and 
is not readily soluble, the absorbed dose is low and therefore the 
radiation dose is negligible.10,120 
c) Radio-labelled Aerosols 
An aerosol is a relatively time-stable two-phase system consisting of 
particles suspended in gas (air). The radio-labelled particles may be 
liquid, solid or a combination of the two. Deposition depends on size 
(mainly), shape, density and electric charge of the particle as well as 
breathing pattern. Aerosols have a mean aerodynamic diameter of 
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about 0.5µm. The larger the particle size, the more the unwanted 
central deposition of the aerosol particles which may obscure 
visualization of adjacent uptake.10,11,154 
i. Tc-diethylenetriaminepentaacetic acid (DTPA) 
Technetium labelled aerosols e.g. 99mTc DTPA, do not allow dynamic 
imaging like 133Xe gas but rather map the distribution of aerated lung 
volume. Radio-labelled aerosols distribution depicts the ventilation 
during the inhalational phase. The inhaled aerosol is deposited on the 
broncho-alveolar spaces with slower washout allowing multiple views 
acquisition in contrast to radioactive gases.120 Tc-99m DTPA is 
delivered to the patient via a nebulizer/ aerosol delivery system 
connected to an oxygen supply flow meter. Air or oxygen is forced 
through the nebulizer at a certain pressure to produce aerosol droplets 
that are inhaled while the exhaled air is trapped in a filter attached to 
the aerosol unit. Central deposition is also common in patients with 
COPD (chronic obstructive pulmonary disease) owing to turbulent flow 
in central airways. The biological half life of 99mTc DTPA in the lungs is 
80±20 minutes in healthy non-smokers, 45±8 minutes in healthy 
passive smokers and 24±9 in healthy smokers due to increased 
alveolar membrane permeability.157 99mTc DTPA aerosol particles cross 
the alveolar-capillary membrane and enter the pulmonary circulation to 
be later cleared by the kidneys. One major downfall in the use of 99mTc  
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DTPA aerosols is that only 2 – 10% of the approximately 30mCi 
(1.11GBq) available in the aerosol generator is actually delivered to the 
lungs while the rest remains airborne or is exhaled.10,11,154 
ii. Technegas 
Technegas, an aerosol, is technetium-labelled with carbon particles 
(graphite crucible). A commercially available technegas generator 
produces very small particles (0.005µm to 0.2 µm) by combustion of 
99mTc eluate at 15000C - 25000C in an argon atmosphere. Technegas 
are hydrophobic particles that tend to grow by aggregation and should 
be used within 10 minutes of generation. They are cleared by alveolar 
resorption and have a biological half-life of 135 hours. Among the 
99mTc-labelled aerosols, Technegas is relatively new, considered to 
behave truly like a gas because of the ultrafine (5 - 150nm) dispersion 
of the 99mTc-labelled carbon particles in contrast to 99mTc DTPA, an 
aerosol which is affected by central deposition due to large particle size 
or in COPD. However in comparison with 81mKr in the Advances in New 
Technologies Evaluating the Localization of Pulmonary Embolism 
(ANTELOPE) study, Technegas increased the number of non-
diagnostic V/Q lung scan results, leading to a demand for further 
additional tests to confirm or exclude PE.120,154 Using Technegas has 
minimized the problem of artefactual hotspots that might hamper 
interpretation in patients with COPD, and according to clinical 
experience is better than the best liquid aerosols.120 
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INTERPRETATION of V/Q Scans 
Different criteria have been advocated for the interpretation of V/Q lung scans in 
patients with suspected PE. For example, in a comparison of observer variability and 
accuracy of the Hull, PIOPED and Gestalt interpretations of V/Q lung scans, all had 
good accuracy and inter-observer variability.158 The Gestalt interpretation is an 
integration of different sets of criteria and the physician’s own experience in 
interpreting lung scintigrams of patients with suspected pulmonary embolism.159 The 
Hull criteria160 are almost similar to the revised or modified PIOPED criteria (Table 4). 
 
The two most widely applied procedures developed with the purpose of enhancing 
the diagnostic accuracy of the scintigraphic approach in PE have initially been 
formalized as clinical investigation trials, the so-called PIOPED4 and the PISA-PED63 
protocols. 
 
Miniati et al in the PISA-PED study proposed using a combination of perfusion scan 
only (Table 5), pretest probability and chest radiography findings to evaluate patients 
with suspected PE.63 These investigators felt that the finding of wedge-shaped 
defects on the perfusion scan can make a diagnosis of PE “irrespective of the 
radiographic findings in the corresponding lung regions”.161 Radiographic findings 
such as oligaemia and consolidation suggesting infarction help when they can be 
distinguished from emphysema, congestive failure and more typical pneumonic 
consolidations. The investigators stated that the chest radiograph is not to be used 
as a surrogate for the ventilation scan. 
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Two recent articles by the proponents of this PISAPED methodology claim an 85% 
PPV and 96% NPV which, when retrospectively applied to the PIOPED II patient 
population are comparable to the CTPA values in the same study (86% PPV, 95% 
NPV). The V/Q scan data using modified PIOPED criteria had a 72.4% PPV and 
96.5% NPV and the number of non-diagnostic studies fell to zero.161,162 
 
The use of the PISA-PED interpretive scheme is of greatest value when used by 
individuals or a closely integrated team with expertise in clinical evaluation, as well as 
radiographic and scintigraphic interpretation. Since this type of universal expertise is 
not always available, the continued use of the ventilation scan is a safer, justifiable 
approach in most medical centers, although its elimination would reduce cost and 
radiation exposure.162 
 
A wedge-shaped perfusion defect is not always simple to characterize on planar 
images. Accordingly, there has been one study that advocates a perfusion-only 
SPECT study as performing better than perfusion-only planar studies and eliminating 
most “non-diagnostic” or intermediate studies.148 A perfusion-only study is 
recommended during pregnancy and patients with suspected massive PE.42 
In the PIOPED protocol, results of the V/Q scan were correlated with the chest 
radiography findings to classify patients into categories with either high, intermediate, 
or low probability of PE.4 
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In the PIOPED study, only 40% of patients with PE had a high probability V/Q scan 
result, whereas another 40% of patients with PE had an indeterminate result and 
14% had a low probability result.4 According to the PIOPED II study, a high 
probability scan is sufficient diagnostic evidence of PE to begin anticoagulation 
therapy and a normal V/Q scan is considered sufficient evidence to exclude PE. 
However, the frequency of low or intermediate probability scan results can be as 
high as 50% to 70%, carrying a 10% to 50% probability of PE. This makes it difficult 
to decide whether or not to begin anticoagulation therapy based on the test result 
alone.40 
 
The original PIOPED study had a high number of inpatients, who constituted 68% of 
the total population studied. PIOPED II had an inpatient population of 11%. 
Inpatients are much more likely to have abnormalities on chest radiographs that 
would potentially interfere with optimal V/Q scan interpretation. Screening patients by 
chest radiography has significantly cut down the non-diagnostic interpretations.138 
 
The use of a number of ancillary scintigraphic findings not used in PIOPED 
subsequently became available, derived from a retrospective review of PIOPED. 
Most of these allow a very low probability or PE absent interpretation. These include 
the stripe sign (activity at the periphery of a perfusion defect), the fissure sign 
(defects that conform to the oblique or horizontal fissure), segmental contour pattern, 
large pleural effusions with matched V/Q scintigraphy findings and no other V/Q scan 
mismatches, radiographic densities with matched V/Q scintigraphy findings in upper 
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or mid-lung zone, perfusion scan better than abnormal chest radiograph, ventilation 
defects worse than perfusion defects (reverse mismatch).138 
 
A retrospective analysis of the PIOPED criteria found errors, e.g., a moderate single 
segmental mismatch was erroneously called low probability. In a subsequent 
publication modifying the original criteria, the single segmental mismatch was 
correctly placed in the intermediate category. Different significance of findings when 
correlated with objective clinical assessment (pretest probability), i.e., a single 
segmental mismatch in a patient with high pretest probability constitutes a high 
probability V/Q scan interpretation.138 
 
Other conditions associated with the appearance of focal defects in a perfusion lung 
scan include compression or invasion of pulmonary vessels by tumors, mediastinal 
lymphadenopathy or granulomata, emphysema (especially in bullous disease), 
interstitial fibrosis, bronchiectasis, pneumonic consolidation and atelectasis, localized 
bronchial obstruction, vasculitis and, arteriovenous fistulae,163-165 163, 164,165 and post radiation 
pneumonitis or fibrosis.42 
 
Harris et al166 examined the feasibility and accuracy of fusing ventilation and 
perfusion data from SPECT V/Q scintigraphy together with computed tomographic 
pulmonary angiography (CTPA) data. In addition, the findings of the technique were 
correlated to the final clinical diagnosis. Thirty consecutive in-patients investigated 
for potential pulmonary embolism were identified retrospectively. Image datasets 
from these two modalities were co-registered and fused using commercial software. 
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Accuracy of the fusion process was determined subjectively by correlation between 
modalities of the anatomical boundaries and co-existent pleuro-parenchymal 
abnormalities. In all 30 cases, SPECT V/Q images were accurately fused with CTPA 
images. Nine patients who had positive CTPA performed as an initial investigation 
had co-localized perfusion defects on the subsequent fused CTPA/ SPECT images. 
Three of the 11 V/Q scans initially reported as intermediate were reinterpreted as low 
probability owing to co-localization of defects with parenchymal or pleural pathology. 
It was suggested that the fusion technique may be clinically useful in patients who 
have non-diagnostic initial investigations or in whom corroborative imaging is 
sought.166 
 
According to the 2009 EANM guidelines for ventilation/ perfusion scintigraphy42,43, 
interpretation of imaging tests such as V/Q Planar and V/Q SPECT should be based 
upon 3 principles:  
1. Basic criteria for reading the images (the so called probabilistic interpretation 
e.g. PIOPED should be done away with since it was based upon old 
techniques), 
2. Knowledge and experience of the interpreter, according to the principle of 
“Gestalt” 
3. Pretest probability in accordance with the principle of holistic interpretation – 
this includes the clinical information and laboratory test. 
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Additionally, for the above principles to be clinically useful, the conclusion should be 
either positive or negative for PE; 
Positive for PE: 
 V/Q mismatch of at least one segment or two subsegments that 
conforms to the pulmonary vascular anatomy i.e. lobar, segmental and 
subsegmental  
Negative for PE: 
 Normal perfusion pattern conforming to the anatomic boundaries of the 
lungs 
 Matched or reverse mismatch V/Q defects of any size, shape or 
number in the absence of mismatch 
 Mismatch that does not have a lobar, segmental or subsegmental 
pattern 
Non-diagnostic for PE: 
 Multiple V/Q abnormalities not typical of specific diseases 
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Table 4 Modified PIOPED II criteria for the diagnosis of PE167, 168 
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Table 5 PISAPED Protocol for perfusion scintigraphy63  
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Table 6 Main differences in the modified PIOPED criteria and Hull criteria158 
 
 
Table 7 Radiation Exposure in adults169-172 169, 170, 171, 172 
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SAFETY in DIAGNOSIS of Pulmonary Embolism (PE) 
A key objective of imaging in pulmonary embolism (PE) is to minimize radiation 
exposure without sacrificing image quality and diagnostic accuracy. The radiation 
exposure (Table 7) using radio-isotopes is 1.2–2mSv42 while for CTPA is 13–
40mSv.173 
 
The increased risk of breast cancer from the radiation exposure with CTPA has 
become a controversial issue. It is probable that premenopausal women represent a 
very significant segment of the population that is evaluated for PE. However, dose 
calculation is very complex because absorption is variable from patient to patient and 
risk data are extrapolated from studies of individuals exposed to large amounts of 
radiation (Hiroshima atomic bomb survivors).174 The linear-non threshold relationship 
between dose and cancer risk is theoretical and not uniformly decided. Breast 
radiation estimates made with 4-slice CT vary from 20 to 60 mSv whereas those 
from V/Q vary, approximately 0.28 to 0.9 mSv.170,175-177 175,176,177A recent report by Einstein 
and coworkers, estimated that 64-slice CTPA delivers a dose of 50 to 80 mSv to the 
breast.178 These reports indicate an enormous difference in radiation dose between 
CTPA and V/Q scans. According to Hurwitz et al, the dose to the female breast for 
V/Q SPECT is only 4% of the dose from MDCT with full dose-saving means.179 This 
may have particular importance in pregnant women with proliferating breast 
tissue.180 
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The estimated radiation exposure from CTPA suggests that a non-negligible 
increase in lifetime attributable risk of cancer exists, particularly to the breasts of 
young women (1 in 143 for a 20-year-old woman and 1 in 284 in a 40-year-old 
woman, with risk further decreasing with increasing age).178,181 It is estimated that 
0.4% of all cancers in the United States are attributable to the radiation from CT 
studies including CTPA, but proper large-scale population-based studies are lacking. 
The American College of Radiology white paper strongly emphasizes that it is the 
responsibility of the imaging physician to be fully educated concerning the radiation 
risks associated with each procedure and, in turn, educate the clinician requesting 
the procedure. Nonetheless, providing diagnostically equivalent options is part of this 
educational process.174 
 
During the first trimester of pregnancy the fetal dose from MDCT is greater than or 
equivalent to that of V/Q scan. The advantage of V/Q SPECT increases after the first 
trimester.182 A 2-day protocol has been suggested in pregnancy. Perfusion-only 
scans should be performed on day 1, using a reduced dose of 99mTc MAA. In most 
patients PE can be excluded on the basis of a normal perfusion pattern. When the 
perfusion pattern is abnormal but not diagnostic of PE, a ventilation study is 
performed on day 2, using an activity deposited in the lung of 20–30 MBq.42 
 
The latency period for potential cancer induction is estimated to be 10–30 years in 
the dose ranges used in CTPA.183 It is an accepted concept among radiation 
biologists and public health officials that the younger the patient is at the time of 
exposure, the greater their lifetime risk of developing nonfatal and fatal cancers. 
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The greater lifetime risk is compounded by the increased biologic susceptibility to 
radiation induced cancer. Thus, CTPA may not always be the best diagnostic option 
in young patients or reproductive-age and peri-menopausal women. If CT is indeed 
justified in this patient population, every effort should be made to reduce the 
radiation dose, shield the patient, and limit the number of CT examinations 
performed.175 
 
Radiation concerns have also been raised with the use of CT venography for 
detection of DVT. There is little to be gained by extending CT imaging to the pelvis or 
lower extremities because isolated pelvic DVT are very rare and ultrasound is very 
accurate for lower extremity DVT.47 
 
Contrast-induced nephropathy is the other safety issue, yet to be evaluated in 
randomized trials. A meta-analysis suggests that the risk is halved with the low-
osmolality contrast agents currently in use and, in PIOPED II, only 1 of 824 patients 
experienced renal failure.40 This patient had diabetes, two contrast injections in 24 
hours and the renal dysfunction was transient. However, PIOPED II excluded 
patients with “abnormal creatinine” levels. Data suggest an increase risk for contrast 
medium-induced nephropathy in pre-existing renal dysfunction, if the serum 
creatinine pre-exposure is 265mol/L (3.0mg/dL).184 In patients presenting to the 
emergency department with suspected PE, contrast nephropathy (an increase of 
serum creatinine of 45mol/L [0.5mg/dL] or a 25% increase within 7 days of CTPA) 
developed in 4% of patients in one study.185 
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To prevent renal dysfunction in low-risk patients, saline hydration appears to be 
beneficial. There are conflicting data on the use of N-acetylcysteine, but it is 
recommended in high-risk patients. In those with pre-existing significant dysfunction 
and diabetics, saline and N-acetylcysteine are recommended. Ideally, a V/Q scan 
would be well suited in these patients.47 
 
Contrast allergic reactions may occur after application of larger volumes of contrast 
media (80–120ml). Mild adverse reactions are encountered after intravenous non-
ionic low osmolarity contrast media in up to 3% of patients. Severe and very severe 
reactions occur much less frequently, with an incidence of 0.22% and 0.04% 
respectively.186 In patients with mild allergy, lower extremities ultrasound is 
recommended. Premedication with steroids has also been recommended if the 
ultrasound is negative and CTPA is to be performed. However, in most of these 
cases V/Q scan is recommended first, reserving CTPA for select cases.47 
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TREATMENT of Pulmonary Embolism (PE) 
Primary therapy consists of thrombolysis using thrombolytic agents and/or 
embolectomy (surgery or catheter) which is reserved for high risk patients i.e. those 
with hemodynamic instability, right ventricular dysfunction, or elevated troponin 
levels secondary to right ventricular microinfarction and elevated brain natriuretic 
peptide (BNP) values.29,62 Secondary prevention for recurrent PE consists of 
anticoagulation with heparin and warfarin or an inferior vena caval filter 
placement.29,187 
 
Adjunctive therapy includes non-steroidal anti-inflammatory drugs (NSAIDs) for pain 
relief. Opoid analgesics are not recommended because they depress the respiratory 
function. Dobutamine – a -adrenoreceptor agonist is effective in treating right heart 
failure and cardiogenic shock.29 
 
Heparin binds and accelerates antithrombin-III enzyme activity which inhibits 
coagulation factors. Heparin thus prevents additional thrombus formation but does 
not dissolve the already existing thrombus. After 5 to 7 days of intravenous or sub-
cutaneous heparin, the residual thrombus begins to stabilize. Heparin can be given 
in 2 forms, unfractionated heparin or as fragments of unfractionated heparin. The 
fragments of unfractionated heparin are low-molecular weight heparins which exhibit 
less binding to plasma proteins, greater bioavailability, better dose response, and 
causes less heparin-induced thrombocytopenia or osteopenia.29 
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Warfarin, an oral anti-coagulant, is a vitamin K antagonist that prevents -
carboxylation activation of coagulation factors II, VII, IX and X. Warfarin takes about 
5 days to become fully effective. Overlapping warfarin treatment with heparin in the 
early 5 days is crucial. Warfarin should be avoided in pregnancy due to the risk of 
embryopathy.29 
 
The efficacy of anticoagulation is monitored by using the International Normalised 
Ratio (INR) levels and the activated partial thromboplastin time. The INR is the ratio 
of the patient’s prothrombin to the control prothrombin multiplied by the international 
sensitivity index. The INR was introduced by the World Health Organization (WHO) 
to standardize control of anticoagulant therapy internationally. According to the 
Prevention of Recurrent Venous Thromboembolism (PREVENT) Trial, the 
recommended target INR levels for VTE should be between 2.0 to 3.0 since low 
rates of recurrence have been observed after 6 months of anticoagulation therapy 
especially if PE is of known origin. The contrary is true for “idiopathic” PE where 
there are increased rates of recurrence in PE after cessation of anticoagulation 
therapy at 6 months.29 
 
The major life threatening side effect of anticoagulation is haemorrhage, especially 
with elevated INR levels (should not exceed 5). If haemorrhage occurs, anti 
coagulants should be withheld and patient given intravenous Vitamin K, 
cryoprecipitate or fresh frozen plasma infusion. In case of heparin overdosage, 
protamine sulphate should be used for reversal.29 
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Inferior vena caval filters are indicated if there is active bleeding that obviates 
anticoagulation or recurrent venous thrombosis unresponsive to anticoagulation. 
Paradoxically, such filters may provide a nidus for clot formation, may fail by allowing 
passage of small to medium-sized clots or may be bypassed by thrombi through 
collateral veins that develop after a PE incident. A common complication of caval 
thrombosis is marked bilateral lower limb swelling secondary to decreased venous 
return. Therefore, such filters may double the venous thromboembolism rate in a 
span of 2 years after placement.29 
 
Thrombolysis, according to MAPPET-3 (Management Strategy and Prognosis of 
Pulmonary Embolism Trial)33, rapidly reverses right heart failure and decreases the 
mortality rate and recurrent PE by dissolving both the anatomically obstructing 
pulmonary arterial thrombus and source of thrombus in the deep lower limb or pelvic 
veins. Thrombolysis prevents the continued release of neurohumoral factors such as 
serotonin which exacerbate pulmonary hypertension. The preferred thrombolytic 
agent is recombinant tissue plasminogen activator (tPA). The major side effect of 
thrombolysis is intracranial haemorrhage. Contraindications to thrombolysis include 
intracranial disease, recent surgery or trauma.29 
 
Embolectomy can be achieved by open surgery or by catheterization and is 
indicated in patients with massive PE and those at risk of intracranial haemorrhage 
with thrombolysis. Pulmonary thromboendarterectomy has been suggested in the 
management of chronic pulmonary hypertension secondary to previous PE leading 
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to reduction or remission of pulmonary hypertension.29 
 
Primary Prevention or rather prophylaxis against PE is advised in those at 
increased risk of PE using mechanical (graduated compression stockings and 
pneumatic compression devices) or pharmacological (anticoagulation) measures. 
Those at increased risk of PE are patients for major surgical procedures especially in 
the lower limb, hip, pelvis, thorax and debulking of tumours.29 
 
Resolution of PE may be prolonged and it is often problematic for lung scintigraphy 
or CTPA to distinguish between residual versus recurrent PE. In a systematic review, 
the percentage of patients with residual thrombi was 87% at 8 days after diagnosis, 
68% at 6 weeks, 65% at 3 months, 57% at 6 months, 52% at 11 months. On the 
basis of such a high percentage of incomplete resolution of PE routine re-imaging 
should be considered after cessation of anticoagulation therapy in patients with PE 
to obtain a new baseline if clinically indicated.188 Resolution of PE may even be more 
variable. Some have reported rapid resolution of a large PE within hours of the onset 
of heparin therapy.189 Fredin and Arborelius190 noted complete restoration of lung 
perfusion in patients with PE within 1 week of diagnosis. On the basis of this rapidly 
changing pattern of perfusion in PE, Coakley191 recommended that imaging tests for 
PE diagnosis should be carried out as soon as possible, preferably within 24 hours 
after onset of symptoms. 
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Follow up of acute PE. Although decreasing over time from a peak 82.3% at one 
month, recurring PE per se is still responsible for over 30% of the deaths at 2 years 
after an acute episode.192 It should also be noted that the fraction of vascular 
obstruction (e.g. above or below 50% of pulmonary perfusion) is a significant 
determinant of overall survival. The most feared long-term consequence of untreated 
or poorly treated acute PE is chronic thrombo-embolic pulmonary hypertension, a 
severely debilitating and potentially fatal condition.32-3432,33 ,34 These considerations 
emphasize the clinical relevance of adequate follow-up after the diagnosis and 
primary therapy of acute PE, both in the short term and in the long term.45 
 
At present, lung perfusion scintigraphy is the imaging procedure of choice for 
monitoring restoration of pulmonary perfusion after embolism (therefore for 
monitoring the efficacy of therapy) and for extended follow-up of patients. This 
technique (which is much more feasible, less expensive, and entails fewer biological 
risks and lower radiation dosimetry to patients than CT-contrast angiography has 
proven to mirror improvement in partial pressure of oxygen in arterial blood, which 
continues up until at least 1 year after the acute episode.45 Lung scintigraphy should 
also be considered an integral component of diagnostic screening in all patients with 
pulmonary hypertension, considering that underlying chronic thromboembolic 
disease frequently sustains such condition34,193, even in patients without a clinically 
obvious episode of acute PE.194 
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Regardless of the diagnostic imaging modality that has ascertained the occurrence  
of acute PE (either on lung scintigraphy and/or CT angiography), a baseline 
pulmonary perfusion scan performed at diagnosis or immediately thereafter should 
be obtained in all patients, to serve as the reference image for subsequent follow-up 
scans assessing restoration of pulmonary perfusion.195 Although timing of such 
imaging follow-up may vary among different clinical practices, the risk of developing 
chronic thromboembolic pulmonary hypertension is best monitored by sequential 
perfusion lung scans performed soon after acute PE (i.e. at 1 and 4 weeks), then at 
3, 6 and 12 months.45 
 
Clinical outcome is considered the ultimate gold standard in judging the clinical utility 
of testing methods in the diagnosis of venous thromboembolism. As it is impossible 
to be sure that PE or deep vein thrombosis has not occurred, recurred or persisted, 
one can only assess the consequences of withholding treatment. Few outcome 
studies have been performed in patients with spiral CT as the only imaging 
technique, or in selected patients who have previously undergone V/Q scintigraphy 
and who have had anticoagulant therapy withheld after negative spiral CT results 
without additional pulmonary angiography.111,196,197 In such studies, the incidence of 
clinically evident recurrent venous thromboembolism during 3–6 months of follow-up 
was found to range from 0% to 4.8%.111,196-198 198 These results are comparable to the 
results of other studies in patients with a negative pulmonary angiogram that 
revealed PE within 1 year in 0.6% to 4.2%.68,199 
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PROBLEM STATEMENT 
SPECT with a superior contrast resolution has been shown to be more sensitive and 
specific with a lower non-diagnostic rate than planar imaging in many nuclear 
medicine studies but it is still not being routinely implemented in V/Q studies at many 
centres including Tygerberg Hospital.  
 
There are many studies on V/Q SPECT using Technegas as a ventilation agent but 
very limited studies available on 81m Kr gas. 
 
It is against this background that this study was designed.  
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OBJECTIVES 
To clinically compare conventional planar and SPECT V/Q imaging using 81mKr gas 
in the diagnosis of pulmonary embolism, in terms of the sensitivity, specificity and 
diagnostic accuracy, with CTPA as the gold standard. 
 
To apply the recent 2009 EANM guidelines in planar and SPECT V/Q image 
interpretation. 
 
To determine the value of the Wells and coworkers model – a simple clinical 
probability testing tool – in the diagnosis of pulmonary embolism. 
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PATIENTS & METHODS 
A. Study area 
The Nuclear Medicine Department of the Tygerberg Hospital, Cape Town, South 
Africa. 
B. Study design 
This prospective study was carried out between October 2008 and October 2009. 
C. Study population 
All patients referred to the Nuclear Medicine Department of the Tygerberg Hospital 
with clinical suspicion of pulmonary embolism. 
D. Sample size 
A total of 104 patients were referred to the Nuclear Medicine Department of the 
Tygerberg Hospital with clinical suspicion of pulmonary embolism. During the 
initiation of the study, the required sample size was 50 patients as calculated using 
Power Analysis for ANOVA Designs200 but only 25 patients were enrolled based on 
the inclusion and exclusion criteria below.91 
E. Inclusion criteria  
 Normal (recent i.e. within 24 hours) chest radiograph$ 
 Normal renal function# 
 No contrast allergy# 
$V/Q scan, #Contrast enhanced CTPA pre-requisites. 
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F. Exclusion criteria 
 Age less than 18 years old 
 Pregnant patients 
 Abnormal chest radiograph 
 Abnormal serum creatinine (180mol/L) / urea (10mmol/L) levels  
 Unstable patient (unable to withstand more than 20minutes of 
imaging)  
Note! 81mKr gas was only available twice a week and thus the study was carried 
out when 81mKr gas was available. 
G. Sampling method 
Consecutive patients were selected using the above inclusion and exclusion criteria 
and underwent the same study protocol. 
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STUDY PROTOCOL 
Ethical and Medico-Legal Aspects 
This study was approved by the Ethics Committee of the Division of Research 
Development and Support at the University of Stellenbosch. Informed consent (see 
Appendix) was obtained from all study participants. The information collected during 
the study was kept confidential – only the research team had access to the study 
participants’ medical records. 
 
Clinical Probability Testing 
An independent clinical history was taken by the principal investigator from the 
patient in addition to the information provided by the referring physician or in the 
patient’s file. Consequently, a score was given to each study participant based on 
the Wells and co-workers model (Table 1).47 
 
Scintigraphic Methods 
Most imaging was done on a dual-head gamma cameras – GE (General Electric) 
Infinia HawkeyeTM (Figure 4) and on some occasions Helix1TM, using a low-energy, 
high-resolution (LEHR) collimator. 
 
Quality control of the dual-head gamma camera was done before each study by an 
experienced physicist based on the National Electrical Manufacturers’ Association 
(NEMA) standards.201,202 
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Both V/Q SPECT and V/Q Planar were done on the same dual-head gamma camera, 
with the patient lying supine position and arms raised above the head (Figure 4 and 
5). 
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Perfusion scintigraphy was performed in a 140keV ± 10% energy window, after 
intravenous injection of resuspended 125 MBq 99mTc labelled macro aggregates of 
albumin (99mTc MAA) through a saline-flushed large bore ( 20G) intravenous 
catheter with the patient lying in the supine position under tidal breathing. The 99mTc 
MAA particles, were resuspended by gently shaking the syringe. The perfusion 
imaging agent (99mTc MAA) was injected only once and used for both SPECT 
perfusion and planar perfusion imaging. 
 
Ventilation scintigraphy was performed in a 190keV ± 10% energy window, with the 
patient inhaling 81mKr gas through an air tight mouth mask (Figure 5) via a 3 way tube 
connected by an inverted Y-connector  which was directed cranially, away from 
patient’s chest to decrease background emission. The mouth mask was held in 
position by a member of the nuclear medicine personnel.81mKr gas was eluted at 
3L/min from a 555 MBq (15mCi) 81Rb generator produced from a cyclotron at 
iThemba Labs, CapeTown South Africa which was only available twice a week. 81mKr 
gas was continuously inhaled by the patient for both SPECT ventilation and planar 
ventilation imaging. 
 
SPECT was performed before planar acquisition. Perfusion and ventilation SPECT 
were both acquired in the same position, using a step and shoot technique of 30 a 
step of 10 seconds each (60 projections per head), on a 128 X 128 matrix over 3600 
(120 projections in total). Perfusion SPECT images were acquired before ventilation 
SPECT images. 
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Total acquisition time for both perfusion and ventilation SPECT was 20 minutes. 
 
Planar imaging was done immediately after SPECT. Planar images consisted of 6 
standard views (ANT, POST, RLAT, LLAT, RPO and LPO) for both perfusion and 
ventilation. Each view had at least 300,000 counts and acquired on a 256 X 256 
matrix. A perfusion image for each standard view was immediately followed by a 
corresponding standard view for the ventilation, in the same position. Total 
acquisition time was 30 minutes. 
 
All images acquired were transferred via network to a HERMES workstation for 
storage and processing. 
 
For accurate interpretation and reporting, Planar ventilation and perfusion images 
were concatenated into 6 standard pairs of views (a total of 12 images), saved and 
viewed next to each other in a HERMES workstation in the following order (ANT 
PERF, ANT VENT; POST PERF, POST VENT, RLAT PERF, RLAT VENT, RPO 
PERF, RPO VENT, LLAT PERF, LLAT VENT, LPO PERF and LPO VENT). 
 
All SPECT perfusion and ventilation images were reconstructed using ordered-
subset expectation-maximization (OSEM) algorithm of 8 iterations and 4 subsets. A 
post-reconstruction 3D Butterworth filter was applied to the perfusion images (cut off 
frequency of 0.8 cycles per cm and an order of 9) and ventilation images (cut off 
frequency of 1.1 cycles per cm and an order of 5). 
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No correction for photon attenuation or scatter was applied. A set of saved co-
registered images of each patient were viewed with a HERMES volume fusion 
display dual application as maximum intensity projection (MIP) movie, coronal, 
transverse, and sagittal slices on a HERMES workstation. 
 
Standard reports were routinely issued mainly based on planar scintigraphic findings 
and modified PIOPED criteria (Table 4) to the referring physician. 
 
V/Q Planar and SPECT images were later evaluated and reviewed separately by an 
experienced nuclear medicine physician and the principal investigator blinded to 
clinical data and CTPA findings. The scintigraphic findings of V/Q Planar and SPECT 
images were later compared with CTPA findings. 
 
Reader confidence in the interpretation of the V/Q Planar and SPECT images was 
qualitatively assessed as; high (100%) if defects can be clearly defined or low (50%) 
if defects cannot be clearly defined. 
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The final interpretation, review and consensus of both V/Q Planar and SPECT was 
based on recent EANM guidelines for ventilation and perfusion scintigraphy42,43, 
Positive for PE: 
 V/Q mismatch of at least one segment or two subsegments that 
conforms to the pulmonary vascular anatomy i.e. lobar, segmental and 
subsegmental 
 
Negative for PE: 
 Normal perfusion pattern conforming to the anatomic boundaries of the 
lungs 
 Matched or reverse mismatch V/Q defects of any size, shape or 
number in the absence of mismatch 
 Mismatch that does not have a lobar, segmental or subsegmental 
pattern 
 
Non-diagnostic for PE: 
 Multiple V/Q abnormalities not typical of specific diseases 
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 CT Pulmonary Angiography 
After V/Q imaging, all study participants were referred for a CT Pulmonary Angiogram 
(CTPA) on the same day. Multislice spiral CT examinations were done on a 40-
detector row scanner (Siemens SOMATOM Sensation) (Figure 6) 
 
 
The patient lying supine and head first in CT scanner, was scanned from superior to 
inferior thoracic inlet, down to the diaphragm during inspiration. Un-enhanced scout 
and axial scan (topogram) was first obtained over 0.2s at 100kV, 40mA, slice 
thickness (0.6mm). 
 
Using an automatic injector / infusion pump connected to a large bore intravenous 
catheter ( 20G) on the upper limb of the patient, a 20ml saline bolus preceded the 
80ml of contrast medium (Ultravist 300) at a flow rate of 4mL per second. The 
contrast medium was followed by a 40ml saline chaser bolus. 
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After an automatic trigger at 80Hu, and when contrast medium was within the 
pulmonary artery, CTPA was acquired. Scan parameters were; 100kV, 135 mA, slice 
thickness (3mm). The entire chest was examined in 10 seconds. 
 
Reconstruction of images was done using CT Angio window (“smooth”; Siemens 
B25f) and lung window (“very sharp”; Siemens B70f) into the axial slices (0.75mm 
slice thickness). The images were later assessed and reported on a separate 
computer workstation by at least two experienced radiologists blinded to the V/Q 
scan results. 
 
Statistical Analysis 
Statistical analysis was done using STATISTICATM version 7.1, in consultation at the 
Centre for Statistical Consultations of the University of Stellenbosch. The Fisher 
exact test was used for comparison of categorical variables. The One-way ANOVA 
was used for comparison of continuous variables (e.g. age); p<0.05 was considered 
significant. 
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RESULTS 
Over a period of 1 year, between October 2008 and October 2009, a total of 104 
consecutive patients were referred to our nuclear medicine department with clinical 
suspicion of pulmonary embolism were assessed. Only 25 patients were included in 
this study. Seventy nine patients were excluded from this study mostly due to 
abnormal serum creatinine / urea levels or renal impairment. 
 
Table 8 Characteristics of the study population (n=25); 
Characteristic Number (Percentage) 
Age  60 years 8/25 (32%) 
Sex (females) 16/25 (64%) 
Referral (outpatients) 13/25 (52%) 
Shortness of Breath 21/25 (84%) 
Chest pain 13/25 (52%) 
Underlying cardiovascular disorders 10/25 (40%) 
Lower limb swelling and pain 6/25 (24%) 
Pulmonary hypertension 5/25 (20%) 
Systemic lupus erythematosus (SLE) 4/25 (16%) 
Palpitations 3/25 (12%) 
Malignancy 3/25 (12%) 
Polycythaemia 2/25 (8%) 
Shortness of breath was the commonest symptom (84%), followed by chest pain 
(52%). DVT was confirmed in one of the patients with lower limb swelling and pain. 
Twenty per cent presented with pulmonary hypertension while 16% had SLE. 
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Table 9A Age against number of patients (n=25); 
The youngest patient was 19 years and oldest was 88 years (only one patient over 
80 years of age). The commonest age group that was referred for PE was 60 to 70 
years. The overall mean age ± std. dev. was 48 ±19 years. 
 
Table 9B Pie Chart of Sex (n=25); 
 
64% (16 out of 25) were females with 28% (7 out of 25) being below the age of 
45years. 
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Table 10 PE Yes or No – V/Q Planar compared to CTPA as gold standard; 
 
V/Q Planar 
CTPA 
No Yes 
Total 
No 19 2 21 
Yes 1 3 4 
Total 20 5 25 
 
Prevalence of PE (4/25) = 16% [5% – 37% at 95% CI] 
Sensitivity (3 /4) = 75% [21% – 99% at 95% CI] 
Specificity (19/21) = 90% [68% – 98% at 95% CI] 
Positive predictive value (3/5) = 60% [17% – 93% at 95% CI] 
Negative predictive value (19/20) = 95% [73% – 100% at 95% CI] 
Diagnostic Accuracy (3+19/25) = 88% [69% – 97%at 95% CI] 
 
 
When V/Q Planar was compared to CTPA as gold standard, 90% of the PE negative 
on CTPA group had PE excluded on V/Q Planar.This was statistically significant 
(p<0.00685). 
 - 93 - 
 
Table 11 PE Yes or No – V/Q SPECT compared to CTPA as gold standard; 
 
V/Q SPECT 
CTPA 
No Yes 
Total 
No 19 2 21 
Yes 1 3 4 
Total 20 5 25 
 
Prevalence of PE (4/25) = 16% [5% – 37% at 95% CI] 
Sensitivity (3 /4) = 75% [21% – 99% at 95% CI] 
Specificity (19/21) = 90% [68% – 98% at 95% CI] 
Positive predictive value (3/5) = 60% [17% – 93% at 95% CI] 
Negative predictive value (19/20) = 95% [73% – 100% at 95% CI] 
Diagnostic Accuracy (3+19/25) = 88% [69% – 97%at 95% CI] 
 
 
When V/Q SPECT was compared to CTPA as gold standard, 90% of the PE 
negative on CTPA group had PE excluded on V/Q SPECT.This was statistically 
significant (p<0.00685). 
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Table 12 PE Yes or No – CTPA according to referrals; 
 
CTPA 
Referrals 
No Yes 
Total 
Outpatients 13 0 13 
Inpatients 8 4 12 
Total 21 4 25 
 
 
 
 
PE was more common amongst inpatients (33%) than outpatients on CTPA. This 
was statistically significant (p=0.00960). 
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Table 13 PE Yes or No – V/Q Planar according to referrals; 
 
V/Q Planar 
Referrals 
No  Yes  
Total 
Outpatients 12 1 13 
Inpatients 8 4 12 
Total 20 5 25 
 
 
 
 
33% of inpatients had PE on V/Q Planar compared to outpatients (8%). This was not 
statistically significant (p=0.10080). 
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Table 14 PE Yes or No – V/Q SPECT according to referrals; 
 
V/Q SPECT 
Referrals 
No  Yes  
Total 
Outpatients 12 1 13 
Inpatients 8 4 12 
Total 20 5 25 
 
 
 
 
33% of inpatients had PE on V/Q SPECT compared to outpatients (8%). This was 
not statistically significant (p=0.10080). 
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Table 15 PE Yes or No – Least Square Means of CTPA against Age; 
 
 
Descriptive Statistics 
Effect  Level 
of 
Factor 
n Age Mean 
Age 
Std. 
Dev. 
Age 
Std. 
Error 
Age 
-95.00% 
Age 
+95.00% 
Total  25 48.04 18.82 3.76 40.27 55.81 
CTPA No 21 50.14 19.26 4.20 41.37 58.91 
CTPA Yes 4 37.00 12.88 6.44 16.50 57.50 
 
On CTPA, the PE positive group had a lower mean age ± std. dev. (37 ± 13 years) 
compared to PE negative group (48 ± 19 years). This was not statistically significant 
(p=0.21). 
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Table 16 PE Yes or No – Least Square Means of V/Q Planar against 
Age;
 
 
Descriptive Statistics 
Effect  Level 
of 
Factor 
n Age Mean 
Age 
Std. 
Dev. 
Age 
Std. 
Error 
Age 
-95.00% 
Age 
+95.00% 
Total  25 48.04 18.82 3.76 40.27 55.81 
V/Q Planar No 20 49.70 18.69 4.18 40.95 58.45 
V/Q Planar Yes 5 41.40 19.92 8.91 16.67 66.13 
 
With V/Q Planar, the PE negative group had a higher mean age ± std. dev. (50 ± 19 
years) compared to PE positive group (41 ± 20 years). This was not statistically 
significant (p=0.39). 
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Table 17 PE Yes or No – Least Square Means of V/Q SPECT against Age; 
 
 
Descriptive Statistics 
Effect  Level 
of 
Factor 
n Age Mean 
Age 
Std. 
Dev. 
Age 
Std. 
Error 
Age 
-95.00% 
Age 
+95.00% 
Total  25 48.04 18.82 3.76 40.27 55.81 
V/Q SPECT No 20 49.70 18.69 4.18 40.95 58.45 
V/Q SPECT Yes 5 41.40 19.92 8.91 16.67 66.13 
 
With V/Q SPECT, the PE negative group had a higher mean age ± std. dev. (50 ± 19 
years) compared to PE positive group (41 ± 20 years). This was not statistically 
significant (p=0.39). 
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Table 18 PE Yes or No – CTPA according to sex; 
 
CTPA 
Sex 
No Yes 
Total 
Females 14 2 16 
Males 7 2 9 
Total 21 4 25 
 
 
 
 
On CTPA, 22% of males were PE positive compared to 13% females. This was not 
statistically significant (p=0.53). 
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Table 19 PE Yes or No – V/Q Planar according to sex; 
 
V/Q Planar 
Sex 
No Yes 
Total 
Females 15 1 16 
Males 5 4 9 
Total 20 5 25 
 
 
 
 
On V/Q Planar, 44% of males were PE positive compared to 6% of females. This 
was statistically significant (p=0.02). 
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Table 20 PE Yes or No – V/Q SPECT according to sex; 
 
V/Q SPECT 
Sex 
No Yes 
Total 
Females 15 1 16 
Males 5 4 9 
Total 20 5 25 
 
 
 
 
On V/Q SPECT, 44% of males were PE positive compared to 6% of females. This 
was statistically significant (p=0.02). 
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Table 21 PE Yes or No – CTPA according to a categorized Wells’ score; 
 
CTPA Wells’ Score 
categorized No Yes 
Total 
PE unlikely (4) 9 0 9 
PE likely (>4) 12 4 16 
Total 21 4 25 
 
 
 
Using the Wells’ score, all patients who were scored as PE unlikely had PE ruled out 
on CTPA. Only 25% with a PE likely Well’s score (>4) went on to be diagnosed with 
PE on CTPA. This was statistically significant (p=0.04581). 
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Table 22 PE Yes or No – V/Q Planar according to a categorized Wells’ score; 
 
V/Q Planar Wells’ Score 
categorized No Yes 
Total 
PE unlikely (4) 8 1 9 
PE likely (>4) 12 4 16 
Total 20 5 25 
 
 
 
Using the Wells’ score, 89% of patients who were scored as PE unlikely had PE 
ruled out on V/Q Planar. Only 25% with a PE likely Well’s score (>4) went on to be 
diagnosed with PE on V/Q Planar. This was not statistically significant (p=0.38761). 
 - 105 - 
 
Table 23 PE Yes or No – V/Q SPECT according to a categorized Wells’ score; 
 
V/Q SPECT Wells’ Score 
categorized No Yes 
Total 
PE unlikely (4) 8 1 9 
PE likely (>4) 12 4 16 
Total 20 5 25 
 
 
 
Using the Wells’ score, 89% of patients who were scored as PE unlikely had PE 
ruled out on V/Q SPECT. Only 25% with a PE likely Well’s score (>4) went on to be 
diagnosed with PE on V/Q SPECT. This was not statistically significant (p=0.38761). 
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Table 24 PE Yes or No – Least Square Means of CTPA against Wells’ score; 
 
 
Descriptive Statistics 
Effect  Level of 
Factor n 
Wells’ 
score 
Mean 
Wells’ 
score 
Std. Dev. 
Wells’ 
score 
Std. Error 
Wells’ 
score 
-95.00% 
Wells’ 
score 
+95.00% 
Total  25 4.66 2.79 0.56 3.51 5.81 
CTPA No 21 4.31 2.90 0.63 2.99 5.62 
CTPA Yes 4 6.50 0.91 0.46 5.05 7.95 
 
On CTPA, a higher mean Wells’ score ± std. dev. (6.5 ± 0.9) increased the likelihood 
of being PE positive while a lower mean Wells’ score ± std. dev (4.3 ± 2.9) tended to 
be PE negative. This was not statistically significant (p=0.15). 
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Table 25 PE Yes or No – Least Square Means of V/Q Planar against Wells’ score; 
 
 
Descriptive Statistics 
Effect  Level of 
Factor n 
Wells’ 
score 
Mean 
Wells’ 
score 
Std. Dev. 
Wells’ 
score 
Std. Error 
Wells’ 
score 
-95.00% 
Wells’ 
score 
+95.00% 
Total  25 4.66 2.79 0.56 3.51 5.81 
V/Q Planar No 20 4.58 2.80 0.62 3.26 5.88 
V/Q Planar Yes 5 5.00 3.02 1.35 1.25 8.75 
 
With V/Q Planar, the PE negative group had a lower mean Wells’ score ± std. dev. 
(4.6 ± 2.8) while the PE positive group had a higher mean Wells’ score ± std. dev. 
(5.0 ± 3.0). This was not statistically significant (p=0.77). 
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Table 26 PE Yes or No – Least Square Means of V/Q SPECT against Wells’ score; 
 
 
Descriptive Statistics 
Effect  Level of 
Factor n 
Wells’ 
score 
Mean 
Wells’ 
score 
Std. Dev. 
Wells’ 
score 
Std. Error 
Wells’ 
score 
-95.00% 
Wells’ 
score 
+95.00% 
Total  25 4.66 2.79 0.56 3.51 5.81 
V/Q SPECT No 20 4.58 2.80 0.62 3.26 5.88 
V/Q SPECT Yes 5 5.00 3.02 1.35 1.25 8.75 
 
With V/Q SPECT, the PE negative group had a lower mean Wells’ score ± std. dev. 
(4.6 ± 2.8) while the PE positive group had a higher mean Wells’ score ± std. dev. 
(5.0 ± 3.0). This was not statistically significant (p=0.77). 
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Table 27 V/Q Planar and V/Q SPECT according to number, size, type of defects, and reader confidence in interpretation compared 
CTPA findings (n=25); 
 
V/Q Planar Defects V/Q SPECT Defects 
ID 
No
. Size Type 
Reader 
Confidence 
PE 
No. Size Type 
Reader 
Confidence 
PE 
Comment 
CTPA 
PE (additional 
findings) 
1 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No 
2 >3 segmental mismatch 
100% Yes 
>3 segmental mismatch 
100% Yes Planar = SPECT Yes 
3 1 segmental ?match 50% No 1 segmental match 100% No Clearly defined on SPECT No (Pulmonary nodule) 
4 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No (Incidental liver lesion) 
5 3 
2segmental
, 
1 sub-
segmental 
match 50% No 3 
2segmental, 
1sub-
segmental 
2segmental 
match, 
1 sub-
segmental 
mismatch 
100% No 
1 sub-segmental defect match 
on planar was a mismatch on 
SPECT 
No (Incidental thyroid lesion, 
kidney cyst) 
6 1 sub-
segmental 
mismatch 100% No 1 sub-
segmental 
mismatch 100% No Planar = SPECT No (Degenerative thoracic spine) 
7 0 - - 
100% No 
0 - - 
100% No Normal No 
8 0 - - 
100% No 
0 - - 
100% No Normal No  (Pneumonic changes) 
9 >3 segmental mismatch 
100% Yes 
>3 segmental mismatch 
100% Yes Planar = SPECT Yes 
10 3 segmental 
2 segmental 
match, 1 non 
segmental 
mismatch 
50% No 2 segmental 
1segmental 
match, 1 
non- 
segmental 
mismatch 
100%  
SPECT detected shine through 
from the contralateral lung, read 
as a segmental match defect on 
Planar 
No 
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Table 27 continued... 
 
V/Q Planar Defects V/Q SPECT Defects 
ID 
No
. Size Type 
Reader 
Confidence 
PE 
No. Size Type 
Reader 
Confidence 
PE 
Comment 
CTPA 
PE (additional 
findings) 
11 >3 segmental mismatch 50% Yes >3 segmental mismatch 100% Yes Clearly defined on SPECT Yes 
12 2 
2 sub-
segmental 
 
mismatch 
100% Yes 
2 
2 sub-
segmental, 
 
mismatch,  
100% Yes 
Planar = SPECT  
Fissure sign noted 
No  
13 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No 
14 3 segmental 
2 reverse 
mismatch,1 
non-segmental 
match 
100% No 
3 segmental 
2 reverse 
mismatch, 1 
non-segmental 
match 
100% No Planar = SPECT 
No (Solitary pulmonary nodule,  
mediastinal lymphadenopathy 
degenerative thoracic spine) 
15 1 segmental non-segmental 
match 
50% No 2 
1  
segmental, 
1 additional 
sub-
segmental 
1 
segmental 
match, 1 
additional sub-
segmental 
mismatch 
100% No 
SPECT detected shine through 
from the contralateral lung, read 
as a non-segmental match defect 
on Planar. (See Figure 7a and 7b) 
No  
16 1 segmental 
reverse 
mismatch 
100% No 
1 segmental 
reverse 
mismatch 
100% No 
Planar = SPECT 
No (Pleural effusion, cysts,  
mediastinal lymphadenopathy) 
17 1 
sub-
segmental 
mismatch 50% No 1 sub-
segmental 
match 100% No 
Matched defect on SPECT-the 
mismatch  on planar was arising 
from overlying tracheal activity 
No (Pleural mass, granulomas) 
18 1 sub-
segmental 
mismatch 100% No 1 sub-
segmental 
mismatch 100% No Planar = SPECT No (Nodule, pleural thickening) 
19 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No (Degenerative thoracic 
spine)  
20 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No (Pleural effusion)  
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Table 27 continued... 
 
V/Q Planar Defects V/Q SPECT Defects 
ID 
No
. 
Size Type 
Reader 
Confidence 
PE 
No. Size Type 
Reader 
Confidence 
PE 
Comment 
CTPA 
PE (additional findings) 
21 1 segmental match 50% No 2 
1 segmental, 
1 additional 
segmental 
All match 100% No 
Clearly defined on SPECT 
Fissure sign noted 
No (Post infective changes, 
granulomas, pleural thickening) 
22 >3 segmental mismatch 100% Yes >3 segmental mismatch 100% Yes Planar = SPECT (Figure 8a 
and 8b) 
No  
23 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No  
24 0 - - 
100% No 
0 - - 
100% No Planar = SPECT No (Solitary pulmonary nodule) 
25 1 segmental mismatch 100% No 1 segmental mismatch 100% No Planar = SPECT (Figure 
9a,9b and 9c) 
Yes 
 
Both V/Q Planar and SPECT had the same number of PE positive cases based on the recent EANM V/Q scintigraphy 
guidelines42,43. V/Q Planar could not clearly resolve defects in 28% cases (7 out of 25) as shown by the 50% reader confidence 
compared to V/Q SPECT which could clearly resolve all cases. CTPA detected additional findings in 52% (13 out of 25). 
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Figure 7a Case One (Below V/Q Planar images) 
Findings; Left apico-posterior non-segmental match defect – arrows (PE negative). PERF=pefusion, vent=ventilation. 
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Figure 7b Case One (Below V/Q SPECT MIP images) 
Findings; Left apico-posterior segmental match defect and an additional single subsegmental V/Q mismatch defect in the superior 
segment of the right lower lobe – arrows (PE negative). 
 
CTPA: Findings; were negative for PE. 
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Figure 8a Case Two (Below V/Q Planar images) 
Findings; multiple segmental V/Q mismatch defects in both lungs (PE positive). P=pefusion, vent=ventilation. 
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Figure 8b Case Two (Below V/Q SPECT MIP images) 
Findings; similar to V/Q Planar. 
 
CTPA: Findings; Negative for PE 
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Figure 9a Case Three (Below V/Q Planar images) 
Findings; a single subsegmental V/Q mismatch defect in the right posterior basal segment – arrows (PE negative). P=pefusion, 
vent=ventilation. 
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Figure 9b Case Three (Below V/Q SPECT images) 
Findings; similar to V/Q Planar. 
 
 - 118 - 
 
Figure 9c Case Three (Below CTPA image) 
Findings; Filling defects in the right lower lobe – arrow (PE positive). 
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Figure 10 Total counts for each patient on V/Q SPECT; 
_________________________________________________________________ 
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DISCUSSION 
V/Q SPECT which has a superior contrast resolution has been shown to be more 
sensitive and specific with a lower non-diagnostic rate than V/Q planar imaging in the 
diagnosis of PE. 
 
This study found that V/Q Planar and V/Q SPECT have a similar performance in 
terms of sensitivity (75%), specificity (90%), negative predictive value (95%) and 
diagnostic accuracy (88%), with CTPA as the gold standard (p=0.00658). The similar 
performances of both V/Q Planar and V/Q SPECT in this study are in contrast to 
previous studies carried in animal models and in clinical practice which consistently 
showed that the use of V/Q SPECT will increase both sensitivity (from 64-71% to 91-
100%) and specificity (from 79-91% to 87-100%) compared with planar imaging.144 
Our V/Q Planar and V/Q SPECT sensitivities were comparable to those of another 
study which reported similar planar and SPECT perfusion scans sensitivities (80%) 
for PE diagnosis.148 
 
In this study, the number of patients positive for PE was similar in both V/Q Planar 
and V/Q SPECT. This is in contrast to a previous study in which PE was more 
prevalent in V/Q SPECT as well as 53% more mismatch defects were noted on V/Q 
SPECT than V/Q Planar.146 On the basis of visual analysis, V/Q SPECT not only 
detected all defects seen on the V/Q Planar images but also clarified any 
uncertainties in the V/Q Planar images in this study. In two cases, V/Q SPECT 
detected additional defects, but did not alter the diagnosis. V/Q Planar in this study 
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had a lower reader confidence i.e. could clearly resolve only 72% of the cases (18 
out of 25) compared to V/Q SPECT (Table 27), which could precisely interpret 100% 
of the cases. V/Q SPECT showed more and better delineated mismatch vs. match 
and segmental vs. non-segmental defects quite in agreement to a previous study.146 
In this study, the inferior reader confidence or lack of clarity in V/Q Planar 
interpretation is in agreement to the fact that only 50 – 80% of cases can be resolved 
by planar scintigraphy.148 This study elucidated that despite the similar performance 
of both V/Q Planar and V/Q SPECT, V/Q SPECT has a better reader confidence. In 
this study, there was no difference in the diagnosis of PE based on the recent EANM 
guidelines42,43 or the modified PIOPED criteria167,168 when all the reports were 
reviewed.  
 
Both V/Q Planar and SPECT had two false positives and one false negative based 
on CTPA as gold standard. The first false positive case, a young male, had 
presented with shortness of breath and pulmonary hypertension diagnosed on 
Echocardiography and had a Wells’ PE likely score of >4. Both V/Q Planar and V/Q 
SPECT imaging noted multiple segmental V/Q mismatch defects (Figure 8a and 8b) 
but CTPA was negative for PE. V/Q scintigraphy has been shown in a previous study 
to have a higher sensitivity (94% - 97.4%) than multidetector CT pulmonary 
angiography (51%) in detecting chronic thromboembolic pulmonary disease as a 
treatable cause of pulmonary hypertension.131 This case illustrates that V/Q imaging 
is more sensitive in detecting chronic PE. 
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The second false positive case had underlying cardiovascular disease (known 
hypertension and dilated cardiomyopathy) with a Wells’ PE unlikely score 4. Both 
V/Q Planar and V/Q SPECT imaging noted two subsegmental V/Q mismatch defects 
in the left apico-posterior segment and left posterior basal segment but CTPA was 
negative for PE. Based on the recent EANM guidelines42,43, this was classified as PE 
positive. 
 
As for the false negative case, the Wells’ score was PE likely (>4) and had a single 
V/Q mismatch subsegmental defect in the right lower lobe seen on both V/Q planar 
and SPECT imaging. Based on the recent EANM guidelines42,43, this was classified 
as PE negative. In this false negative case, CTPA positively confirmed features of 
PE in the right lower lobe (Figure 9a, 9b and 9c). 
 
In the original PIOPED study4, the large number (44%) of non-diagnostic 
interpretations was related to the fact that 68% of the study population comprised 
inpatients who were more likely to have underlying cardiopulmonary disease, such 
as pneumonia, chronic obstructive lung disease and pleural effusions that tend to 
cause “triple matches”. In this study, 48% (12 out of 25 patients) were inpatients and 
all patients who were enrolled, had a normal or near-normal chest radiograph 
making interpretation less difficult. PE was more common amongst inpatients (33%) 
on CTPA (p=0.00960), V/Q Planar and V/Q SPECT compared to outpatients (0% on 
CTPA [p=0.00960], 8% on V/Q Planar and V/Q SPECT) in this study. 
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Assessment of the clinical probability can be accomplished empirically or by means 
of a prediction rule. The latter is preferable over empirical assessment, especially for 
less experienced clinicians. Clinical probability tests like the Wells’ score used in this 
study can be rapidly obtained by a clinician at the bedside and is reproducible.47 The 
Wells and coworkers model47 seems better suited to rule out rather than to rule in the 
diagnosis of PE, and its performance is likely to be better in clinical settings. In this 
study, all patients who were scored as PE unlikely on Wells’ score ( 4) had PE ruled 
out on CTPA (p=0.04581) as well as 89% on V/Q SPECT and V/Q Planar. Only 25% 
with a PE likely on Wells’ score (>4) went on to be diagnosed with PE on CTPA 
(p=0.04581), V/Q Planar and V/Q SPECT. 
 
There is a misconception that SPECT imaging takes longer to acquire than 
traditional planar imaging. With the use of multi-head gamma cameras and modern 
computing, SPECT acquisition times are often faster than typical planar studies.9 
Most centers use dual headed detectors to shorten the time of the examination.138 In 
this study, the total acquisition time of V/Q SPECT was 20 minutes (10 minutes less 
than planar acquisition) comparable to other studies done on V/Q SPECT with 
Technegas.129,145,147 This time would have been shortened by 50% if the gamma 
cameras used were capable of simultaneous dual radioisotope energy acquisition of 
both ventilation and perfusion SPECT. The only concern is down scatter of higher 
energy 81mKr gas (190Kev) into the lower energy 99mTc MAA (140keV) which may 
fill in true defects in perfusion images leading to false negatives. Therefore, in this 
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study, ventilation and perfusion were acquired separately. It is not unforeseeable in 
the near future, that gamma cameras with state of art technology may be able to use 
simultaneous dual radioisotope energy acquisition in V/Q SPECT. 
 
Many studies have been done on V/Q SPECT using Technegas because of limited 
availability of 81mKr gas. In this study, perfusion SPECT was performed first followed 
by ventilation SPECT, and immediately thereafter planar perfusion was followed by 
planar ventilation imaging according to our study protocol. However, in clinical 
practice either perfusion or ventilation can be done first with 81mKr gas. Background 
emission was cut back in this study by using better, air tight, hand-held mouth masks 
with a 3 way tube connected by an inverted Y-connector, which was directed 
cranially, away from the patient’s chest to decrease background emission. 81mKr gas 
produced good quality interpretable images with sufficient counts (Figure 10). 
 
V/Q SPECT has the definite advantages of being better able to quantify the extent of 
perfusion abnormalities and can assess reperfusion after PE (especially in follow 
up), something not easily done with CTPA,141,146 as well as having a lower radiation 
dose. V/Q SPECT unlike V/Q Planar permits the application of advanced image-
processing techniques. With the help of these techniques, the detection of match 
and mismatch defects can be automated and objectified. The automated analysis 
has a significant improvement in the detection rate of pathological lesions especially 
in complex cases with heterogeneous ventilation and perfusion (e.g. in COPD 
patients) compared to conventional visual image interpretation.149 In this study, 
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image interpretation was based on conventional visual analysis and the various 
advanced image-processing options offered by V/Q SPECT such as planar 
regeneration, correction for photon attenuation or scatter, V/Q Quotient quantification 
as has been suggested by various studies151-153 were not explored. Presently, it is 
not known if such techniques would have added more value to our V/Q SPECT 
findings. 
 
CTPA detected conditions not visualized on V/Q scintigraphy such as mediastinal 
lymphadenopathy, solitary pulmonary nodules, pneumonic changes, pleural disease, 
degenerative thoracic spine changes, incidental thyroid lesion, liver lesion and 
kidney cyst in 52% (13 out of 25) of the CTPA examinations performed in this 
study(Table 27). This confirmed that CT is better in depicting other conditions than 
V/Q scintigraphy109 and correlates with other studies where other conditions have 
been reported to have been found in 11% to 70% of CT examinations performed for 
suspected acute PE.111-116 
 
There is a potentially increased risk of breast cancer from the radiation exposure 
with CTPA, especially with premenopausal women, since they tend to represent a 
very significant segment of the population that is evaluated for PE174 as collaborated 
in this study where 28% (7 out of 25) were premenopausal (less than 45 years of 
age). Furthermore, there were more males (44% on V/Q Planar and V/Q SPECT 
(p=0.02), 22% on CTPA) with PE positive compared to females (6% on V/Q Planar 
and V/Q SPECT (p=0.02), 13% on CTPA) in this study. 
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A multidisciplinary approach should be used in developing sequential diagnostic 
algorithms (Figure 11 [based on this study]) for patients with suspected PE.43 
Imaging physicians should be fully educated concerning the radiation risks 
associated with each diagnostic procedure for PE and, in turn, educate the clinician 
requesting the procedure. 
 
Figure 11 Diagnostic alogrithm for PE; 
 
 
$Some of the CTPA contraindications include abnormal serum creatinine or urea 
levels, contrast allergy and excess BMI. 
 
 
Clinical suspicion of PE 
Blood analysis 
(Serum D-dimer, Creatinine & Urea levels)  
Chest X-ray 
± ECG, ± ECHO, ± Lower Limb USS 
Clinical probability testing 
e.g. the Wells’ and co-workers model 
PE unlikely PE likely 
CTPA V/Q Scan 
Normal Chest X-ray 
or any CTPA 
contraindication$ 
 
   
  
 
Abnormal 
Chest X-ray  
Look for 
Alternative 
Diagnoses 
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Study Limitations: 
Individually, symptoms, signs, or common laboratory tests have limited diagnostic 
power but jointly, they may provide accurate assessment of the clinical probability of 
PE. In this study, all patients were assumed to be D-dimer positive due to the fact 
that the D-dimer levels of each patient by the referring physician were done at 
different laboratories, hospitals and on different dates, thus impossible to compare. 
 
Comparison of 81mKr gas with other ventilation imaging agents was not possible due 
to radiation safety concerns and costs. 
 
Since there is no adequate gold standard, the clinical outcome is considered the 
ultimate gold standard – although it is argued that clinical outcome can be erroneous 
in patients with small pulmonary emboli that undergo spontaneous lysis and/or do 
not recur or if patients are lost on follow up; and only autopsy can provide a definitive 
diagnosis in patients who die after diagnosis of PE. A normal V/Q scan essentially 
excludes the diagnosis of PE (1% VTE rate in follow-up).4,68 In this study, follow up of 
patientswas not done. It would have been ideal to follow up patients, to determine 
the VTE rate especially in the PE negative cases. It would have also been ideal to 
repeat V/Q Planar and/ or V/Q SPECT in the PE positive cases after anticoagulation 
to ascertain efficacy of therapy, progression of disease (residual vs. new PE). In a 
way, this would have contributed in risk stratification and prognosis of PE positive 
patients. 
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The small study sample based on the strict inclusion and exclusion criteria did not 
permit statistical analysis of trends. 
 
Advanced image-processing options offered by V/Q SPECT were not explored. 
Presently, it is not known if such techniques would have added more value to our 
V/Q SPECT findings. 
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CONCLUSION 
Based on this study, using Krypton 81m gas a ventilation imaging agent, V/Q Planar 
and V/Q SPECT had a similar diagnostic performance in the diagnosis of PE, in 
patients with a normal or near normal chest X-rays with CTPA as a gold standard. 
V/Q SPECT had a better reader confidence than V/Q Planar. 
 
A dichotomous or binary system (PE yes or no) according to the recently published 
EANM guidelines can be reliably applied in V/Q image interpretation. 
 
A simple clinical probability testing tool such as the Wells and coworkers model can 
be useful in conjunction with V/Q scintigraphy in the diagnosis of PE. 
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